Fragile X Syndrome

🔗

Mappings

MONDO

MONDO:0010383 fragile X syndrome

Orphanet lists MONDO:0010383 as an exact cross-reference for fragile X syndrome.

ICD-10-CM

ICD10CM:Q99.2 Fragile X chromosome

Orphanet lists ICD-10 Q99.2 as an exact cross-reference for fragile X syndrome.

ICD-11 Foundation

icd11f:1524287677 Fragile X chromosome

Orphanet lists ICD-11 LD55 as an exact cross-reference; the local ICD-11 Foundation ontology represents this as icd11f:1524287677.

👪

Inheritance

1

X-linked dominant inheritance HP:0001423

Orphanet classifies fragile X syndrome as X-linked dominant; clinical expression is typically more severe in affected males and variable in heterozygous females.

X-linked dominant inheritance

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"X-linked dominant"

Orphanet directly lists X-linked dominant inheritance for Fragile X syndrome.

◆

Subtypes

1

Full Mutation

More than 200 CGG repeats with methylation, full syndrome expression in males.

◈

Mechanistic Hypotheses

1

Canonical FMR1 Silencing / FMRP Loss / Synaptic Translation Dysregulation Model

canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model CANONICAL

Evidence balance 1 support

Fragile X syndrome (FXS) is caused by CGG-trinucleotide repeat expansion (>200 repeats) in the 5' UTR of FMR1 on Xq27.3, leading to hypermethylation and transcriptional silencing of FMR1 and loss of its protein product FMRP. FMRP is an RNA-binding protein that represses translation of hundreds of synaptic mRNAs at dendrites and is required for the metabotropic glutamate receptor (mGluR)-dependent regulation of synaptic protein synthesis. Loss of FMRP produces excessive and decoupled local protein synthesis, leading to exaggerated mGluR-LTD, abnormal dendritic spine morphology, altered excitatory/inhibitory balance, and the cognitive and behavioral phenotypes of FXS. mGluR5 antagonists, GABAergic modulators, and IGF-1 / BDNF / MAPK-pathway perturbation studies in Fmr1-knockout mice and human iPSC-derived neurons all corroborate the canonical FMRP-loss / dysregulated synaptic-translation model.

Retained as CANONICAL with hub-and-spoke annotation. The 2026 openscientist hypothesis-search report (kb/hypotheses/Fragile_X_Syndrome/canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model) confirms CGG-expansion → FMR1 silencing → FMRP loss as the central lesion, with dCas9-Tet1 demethylation rescuing FMR1 expression and neuronal phenotypes (>5% FMRP restoration sufficient) providing the strongest causal proof. FMRP target mRNAs are enriched among de novo mutations in schizophrenia, autism, and intellectual disability, validating FMRP as a central translational regulator. Three critical refinements: (1) clinical translation failure — multiple Phase 2b mGluR5-antagonist trials failed in FXS patients, attributed by expert consensus to trial design but the question remains open; (2) mechanistic scope must expand beyond synaptic translation — FMRP has critical non-synaptic functions in genome stability (R-loop prevention), chromatin regulation (BRD4), astrocyte-autonomous GABA transport, and metabolic programming; (3) phenotypes are age- and condition-dependent — enhanced mGluR-LTD is restricted to the P30–60 age window in mice; spine density normalizes by adulthood while dendritic complexity progressively worsens. The report recommends annotating the model as a hub-and-spoke architecture in which FMRP loss disrupts multiple parallel effector arms, with synaptic translation being the best-studied but not the sole driver of clinical phenotypes.

Deep research

OpenScientist citations 55 citations 2026-05-23T23:04:42.114391

Show evidence (1 reference)

PMID:24346713 SUPPORT Other

"Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations."

Canonical mechanism reference used as the seed for the hypothesis-search deep-research run.

?

Discussions and Knowledge Gaps

6

Which tissue mechanisms connect FMRP deficiency to the connective-tissue and craniofacial manifestations of fragile X syndrome?

KNOWLEDGE GAP unresolved_connective_tissue_and_craniofacial_mechanisms

Attached to

phenotypes#Elongated Face phenotypes#Large Ears phenotypes#Protruding Ears phenotypes#Joint Hypermobility phenotypes#Pes Planus phenotypes#High Palate phenotypes#Mandibular Prognathia phenotypes#Pectus Excavatum phenotypes#Scoliosis phenotypes#Mitral Valve Prolapse phenotypes#Aortic Root Dilatation

The prior physical-phenotype node restated a clinical feature list and assigned fibroblast and developmental processes without mechanistic evidence. The clinical literature supports these findings, but the cited review explicitly leaves the biochemical and molecular explanation unresolved; no shared causal mechanism is asserted here.

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"Although a specific ab- normality of the connective tissue has not yet been shown, the prevalence of connective tissue signs has sug- gested that there is an underlying connective tissue anomaly, perhaps similar to that observed in CTDs (in particular, Marfan Syndrome and Ehlers-Danlos..."

The review explicitly identifies the unresolved molecular basis of connective-tissue signs.

Does increased developmental Sertoli-cell proliferation explain macroorchidism in human fragile X syndrome as it does in Fmr1 knockout mice?

HUMAN MODEL MISMATCH macroorchidism_model_to_human_gap

Attached to

phenotypes#Macroorchidism

A mouse experiment establishes increased Sertoli-cell proliferation, but the human clinical sources document enlargement and age dependence without establishing that cellular intermediate. The mouse mechanism is retained as a research lead rather than a proven human causal edge.

Proposed experiments

Compare human testicular cell composition

human_sertoli_cell_composition

Quantify Sertoli-cell abundance and developmental proliferation markers in available FXS and age-matched control testicular specimens to test whether the mouse cellular mechanism translates to humans.

Show evidence (1 reference)

PMID:9421410 SUPPORT Model Organism

"We conclude that macroorchidism in Fmr1 knockout male mice is caused by an increased rate of Sertoli cell proliferation."

Direct model-organism evidence; the corresponding human mechanism remains unverified.

Which phenotype-specific intermediates explain the remaining neurologic, behavioral, growth, ocular, gastrointestinal and middle-ear findings?

KNOWLEDGE GAP phenotype_specific_neurodevelopmental_and_multisystem_intermediates

Attached to

phenotypes#Sleep Disturbance phenotypes#Gastroesophageal Reflux phenotypes#Attention Deficit Hyperactivity Disorder phenotypes#Delayed Speech and Language Development phenotypes#Abnormal Speech Pattern phenotypes#Hypotonia phenotypes#Chronic Otitis Media phenotypes#Macrocephaly phenotypes#Strabismus phenotypes#Aggressive Behavior phenotypes#Obesity phenotypes#Delayed Gross Motor Development phenotypes#Recurrent Hand Flapping phenotypes#Self-injurious Behavior

FMRP loss and synaptic dysfunction establish the broad neurodevelopmental disease mechanism, but the reviewed clinical evidence does not isolate a causal chain for each of these findings. Sleep and behavioral features have plausible neural contributors; growth, ocular, gastrointestinal and otological findings require separate tissue explanations. These phenotype associations are retained without adding arrows solely from coexistence.

Did the mGluR5-antagonist trials fail because the synaptic translation arm does not drive the clinical phenotype, or because they treated adolescents and adults, after the developmental window, against behavioral rating endpoints with a high placebo response?

KNOWLEDGE GAP OPEN fxs_mglur5_translation_window

Attached to

pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation mechanistic_hypotheses#canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model clinical_trials#NCT02920892

The mGluR theory's one testable clinical prediction has now failed twice over: two phase 2b mavoglurant trials in adolescents and adults missed their behavioral primary endpoints, and the later FXLEARN phase 3 trial in 3 to 6 year olds missed its primary language outcome. Yet mavoglurant did move biobehavioral measures in the same patients, so the drug was reaching its target. Nothing published so far separates the two explanations, and the distinction matters for what this entry asserts: whether the synaptic translation node is the therapeutically relevant driver of the cognitive and behavioral phenotype, or one arm among several. Expert reviews attribute the gap to trial design rather than to the model, but that is opinion rather than a result and should not be curated as a finding.

Proposed experiments

Early-intervention trial with EEG biomarkers as co-primary endpoints

fxs_early_intervention_eeg_endpoint_trial

Randomized controlled trial of an mGluR5 modulator, with or without a GABA-B agonist, in children aged 2 to 6, using auditory inter-trial phase coherence and resting gamma power as co-primary endpoints alongside adaptive behavioral measures. Both EEG measures are abnormal in Fmr1 knockout mice from early postnatal ages and have human counterparts, which makes them candidate pharmacodynamic markers for a population in whom behavioral rating scales perform poorly.

Would support

pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation

Supporting outcome

EEG measures normalize and developmental trajectory improves, indicating that treatment timing rather than model validity explains the earlier failures.

Refuting outcome

EEG measures normalize while behavior does not, indicating that correcting the synaptic translation arm is insufficient and that the parallel effector arms carry a substantial part of the clinical phenotype.

Show evidence (2 references)

PMID:30451888 SUPPORT Human Clinical

"Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate any behavioral benefits in two 12-week, randomized, placebo-controlled, double-blind, phase IIb studies in adults..."

Documents the failure of the mGluR theory's central therapeutic prediction in the age group tested, and the mismatch with the preclinical result that motivated the trials.

PMID:30653533 SUPPORT Human Clinical

"The study shows that negative modulation of mGluR5 activity improves eye gaze behavior and alters sympathetically-driven reactivity to faces in patients with FXS, providing preliminary evidence of this drug's impact on behavior in humans with the disorder."

An eye-tracking biobehavioral probe embedded in the same trials did detect a drug effect, which is why the endpoint explanation for the failure cannot be dismissed.

Are the nuclear genome-protection and glutaminase-dependent metabolic consequences of FMRP loss independent contributors to the fragile X phenotype, or downstream of, or incidental to, the cytoplasmic translational defect?

KNOWLEDGE GAP OPEN fxs_nonsynaptic_effector_arms

Attached to

pathophysiology#FMRP loss of translational repression pathophysiology#Excess translation of chromatin regulators

FMRP loss has documented consequences that this entry's pathograph does not connect to any phenotype. Patient fibroblasts accumulate twice the double-strand breaks of controls, with breaks colocalizing with R-loop forming sequences under replication stress; patient iPSC-derived neurons show reduced glutaminolysis and impaired anaplerotic supply to the TCA cycle. Both are measured in patient-derived cells, so neither is a model artifact, but neither has been traced to a neural or clinical outcome, and no experiment has separated nuclear from cytoplasmic FMRP function. Until that is done, the entry curates these as observations rather than as arms of the causal chain, and the astrocytic and chromatin arms are curated as nodes only because each has an intervention that reverses a downstream phenotype.

Proposed experiments

Compartment-restricted FMRP rescue

fxs_nuclear_vs_cytoplasmic_fmrp_rescue

Express nuclear-localization-tagged FMRP against nuclear-export-tagged FMRP in FMRP-null cells and neurons, then measure protein synthesis rate, mGluR-dependent long-term depression, double-strand breaks, R-loops, chromatin marks, and glutaminolysis in each condition.

Would support

pathophysiology#FMRP loss of translational repression

Supporting outcome

Cytoplasmic FMRP alone corrects the genome-instability and metabolic readouts, showing they are downstream of the translational defect and need no separate arm in the model.

Refuting outcome

Only nuclear FMRP corrects the genome-instability readouts, establishing an effector arm that the synaptic translation formulation cannot account for.

Show evidence (2 references)

PMID:32966779 SUPPORT In Vitro

"We report that the genomes of FXS cells are inherently unstable and accumulate twice as many DSBs as those from an unaffected control."

Establishes the genome-instability observation in patient-derived cells. The study does not link it to any neural or clinical phenotype, which is the gap.

PMID:41557506 SUPPORT In Vitro

"Metabolic tracing in FXS neurons demonstrates a dearth of glutamine deamidation to glutamate, which reduces anaplerosis into the TCA cycle, potentially hindering the bioenergetic and biosynthetic functions of mitochondria."

Establishes the metabolic observation in patient iPSC-derived neurons. The authors themselves hedge the disease link, and no causal test of it has been reported.

Is exaggerated mGluR-dependent long-term depression a general property of FMRP loss, or an artifact of a narrow mouse age window and the pharmacological and metabolic conditions of the slice recording?

HUMAN MODEL MISMATCH OPEN fxs_mglur_ltd_age_and_condition_dependence

Attached to

pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation

Exaggerated mGluR-LTD is the signature electrophysiological phenotype of the canonical model, but in the Fmr1 knockout mouse it appears only between P30 and P60, and only when NMDA receptors are pharmacologically blocked; the same study concludes that hyperactive GluN2B-containing NMDA receptors, not the mGluR arm alone, underlie the difference. The phenotype has never been demonstrated in human brain tissue or human neuronal preparations. So the entry's mGluR node rests on a mouse measurement whose scope is narrower than the claim usually made from it, and the translational status of the phenotype is the open question rather than its existence.

Proposed experiments

mGluR-dependent long-term depression in human FXS neural tissue

fxs_human_mglur_ltd_organoid_test

Test for exaggerated mGluR-dependent long-term depression in patient iPSC-derived brain organoids and, where available, acute human cortical tissue, under both standard and NMDA-receptor-blocked conditions and across differentiation stages matched to the mouse age window.

Would support

pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation

Supporting outcome

Human FXS neural tissue shows exaggerated mGluR-dependent long-term depression without requiring NMDA-receptor blockade, confirming the phenotype translates.

Refuting outcome

No difference in human tissue, or a difference only under the same pharmacological conditions required in mouse, confining the phenotype to the model system.

Show evidence (1 reference)

PMID:27656021 SUPPORT Model Organism

"As expected, in the presence of APV, we found more LTD in the mouse KO than in WT. This, however, was only observed in the p30-60 age group."

States both limits on the phenotype in one sentence pair: it requires NMDA-receptor blockade and it is confined to a single postnatal window.

⚙

Pathophysiology

9

Somatic CGG Repeat Expansion (FMR1)

The FMR1 CGG repeat is processed by an aberrant DNA mismatch-repair route: the MutSβ (MSH2-MSH3) recognition complex, with the MutLγ (MLH1-MLH3) effector complex acting downstream, is required for germline and somatic CGG expansion in knock-in mouse models of the fragile X-associated disorders. This is the CGG-class instance of the module's aberrant-MMR machinery and lies upstream of the full-mutation methylation silencing that abolishes FMRP. Unlike the CAG/CTG disorders, ongoing post-mitotic somatic expansion is not established as the rate-limiting driver of fragile X syndrome onset — in humans the premutation to full-mutation transition is predominantly a maternal-germline / early-embryonic event and the silencing is already set developmentally — so this node conforms only at the molecular MMR-processing level, not at the module's somatic post-mitotic expansion node.

FMR1 hgnc:3775 MSH3 hgnc:7326

mismatch repair GO:0006298 ↕ DYSREGULATED

Downstream

FMR1 full-mutation transcriptional silencing Aberrant MMR processing of the CGG tract contributes to the expansion that produces the full-mutation allele, which in turn triggers promoter hypermethylation and transcriptional silencing of FMR1. The expansion step itself is omitted from this edge.

Show evidence (2 references)

PMID:26420841 SUPPORT Model Organism

"MSH3, the MSH2-binding partner in the MutSβ complex, is required for 98% of germ line expansions and all somatic expansions in this model."

A Fragile X mouse model shows the MutSβ (MSH2-MSH3) complex is required for all somatic CGG expansion, the CGG-class instance of the module's aberrant-MMR mechanism.

PMID:30312299 SUPPORT Model Organism

"MLH1/MLH3 (MutLγ), a protein complex that can act downstream of MutSβ in MMR, is also required for all germ line and somatic expansions."

The same Fragile X model shows the MutLγ (MLH1-MLH3) effector complex acting downstream of MutSβ is required for CGG expansion, with EXO1 protective — the machinery of the module's amplifier node.

FMR1 full-mutation transcriptional silencing

The canonical initiating event is expansion of the FMR1 5' UTR CGG repeat above 200 repeats. Full-mutation alleles become epigenetically silenced in differentiated cells, which reduces or abolishes fragile X messenger ribonucleoprotein (FMRP).

FMR1 hgnc:3775 ↓ DECREASED

Downstream

FMRP loss of translational repression Epigenetic silencing of the full-mutation FMR1 allele decreases FMRP, removing a key RNA-binding translational repressor.

Show evidence (3 references)

PMID:28420439 SUPPORT Human Clinical

"more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS."

This review establishes the full-mutation CGG expansion as the dominant molecular diagnosis for fragile X syndrome.

PMID:27713816 SUPPORT In Vitro

"Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory."

Patient-derived stem-cell and neuronal differentiation work supports epigenetic silencing of full-mutation alleles and consequent FMRP loss.

PMID:29456084 SUPPORT In Vitro

"Targeted demethylation of the CGG expansion by dCas9-Tet1/single guide RNA (sgRNA) switched the heterochromatin status of the upstream FMR1 promoter to an active chromatin state, restoring a persistent expression of FMR1 in FXS iPSCs."

Removing the methylation reactivates FMR1 and rescues the electrophysiological abnormality of the derived neurons, so methylation-dependent silencing is the operative lesion at this node rather than a correlate of it.

FMRP loss of translational repression

FMRP normally binds coding and non-coding RNAs and restrains translation at dendritic and synaptic locations. Loss of FMRP removes this brake, increasing basal protein translation and uncoupling translation from neuronal activity.

neuron CL:0000540

FMR1 hgnc:3775 ↓ DECREASED

negative regulation of translation GO:0017148 ↓ DECREASED

Downstream

Synaptic protein synthesis and mGluR signaling dysregulation Loss of FMRP increases basal translation and disrupts mGluR-triggered translational control at synapses.

Excess translation of chromatin regulators FMRP also represses transcripts encoding chromatin-associated regulators, so its loss lifts that brake as well as the synaptic one.

Astrocytic GABA transport dysregulation FMRP is lost in astrocytes as well as neurons, and astrocyte-restricted Fmr1 deletion alone is sufficient to disturb astrocytic GABA handling.

Show evidence (4 references)

PMID:24346713 SUPPORT Other

"Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations."

This directly supports FMRP as a translational repressor at neuronal dendritic and synaptic sites.

PMID:22483044 SUPPORT Other

"FMRP is an mRNA-binding protein that functions at many synapses to inhibit local translation stimulated by metabotropic glutamate receptors (mGluRs) 1 and 5."

This supports the mechanism linking FMRP loss to dysregulated local synaptic translation.

PMID:21784246 SUPPORT Model Organism

"We developed a brain polyribosome-programmed translation system, revealing that FMRP reversibly stalls ribosomes specifically on its target mRNAs."

Identifies the molecular action that is lost at this node. FMRP holds ribosomes in a reversible stall on its own target transcripts, so removing it releases those transcripts specifically rather than raising translation indiscriminately.

+ 1 more reference

Synaptic protein synthesis and mGluR signaling dysregulation

With FMRP absent, basal translation is enhanced and mGluR1/5-linked local translation is no longer appropriately regulated. This distorts the experience-dependent protein synthesis needed for synaptic plasticity.

neuron CL:0000540

regulation of synaptic plasticity GO:0048167

Downstream

Dendritic spine and synapse maturation abnormality Dysregulated local translation alters synaptic plasticity programs that shape dendritic spine and synapse maturation.

Neurodevelopmental circuit dysfunction Abnormal synaptic protein synthesis and plasticity impair the neural circuit functions required for cognition, social behavior, and attention.

Show evidence (2 references)

PMID:24346713 SUPPORT Other

"In the absence of FMRP, the basal protein translation is enhanced and not responsive to neuronal stimulation."

This supports enhanced basal protein translation after FMRP loss.

PMID:22483044 SUPPORT Other

"Recent studies on the biology of FMRP and the signaling pathways downstream of mGluR1/5 have yielded deeper insight into how synaptic protein synthesis and plasticity are regulated by experience."

This places mGluR1/5-linked signaling and synaptic protein synthesis within the fragile X pathophysiology framework.

Dendritic spine and synapse maturation abnormality

FMRP loss disrupts synapse structure and dendritic spine maturation. Patient and model-system literature consistently links fragile X syndrome to altered structural and functional synaptic plasticity, with cell-type and brain-region-specific changes in synapse density and spine morphology. The spine component of this node is age dependent in the mouse rather than static: density is raised during early development and returns to wild-type levels by adulthood, while dendritic branching complexity falls progressively with age. Curate adult structural claims accordingly.

neuron CL:0000540

synapse organization GO:0050808 protein localization to synapse GO:0035418

Downstream

Neurodevelopmental circuit dysfunction Altered synapse and spine maturation disrupts network-level signaling needed for cognition and behavior.

Neuronal hyperexcitability Synaptic dysregulation contributes to increased neuronal excitability and seizure susceptibility in a subset of affected individuals.

Show evidence (4 references)

PMID:33013316 SUPPORT In Vitro

"Loss of FMRP, as in fragile X syndrome (FXS), is a leading monogenic cause of autism and results in altered structural and functional synaptic plasticity, widely described in the hippocampus and cortex."

This supports altered structural and functional synaptic plasticity as a downstream effect of FMRP loss.

PMID:33013316 SUPPORT In Vitro

"Utilizing a cortical-striatal co-culture model, we find that striatal medium spiny neurons (MSNs) lacking FMRP fail to make normal increases in PSD95 expression over a short time period and have significant deficits in dendritic spine density and colocalized synaptic puncta at the later measured..."

This in vitro model links FMRP loss to abnormal postsynaptic marker expression, dendritic spine density, and synaptic puncta.

PMID:41982083 SUPPORT Model Organism

"In contrast, spine density was increased in both apical and basal dendrites during early development but normalized to wild-type levels in adulthood."

Golgi-Cox analysis across four developmental stages from P14 to P150 shows the raised spine density is a developmental feature that resolves, so this node should not be read as asserting a persistent adult spine excess.

+ 1 more reference

Neurodevelopmental circuit dysfunction

Synaptic translation and spine abnormalities converge on disrupted neural circuit development and function. This branch accounts for the core cognitive and behavioral manifestations of fragile X syndrome, including intellectual disability, autistic behavior, and hyperactivity.

neuron CL:0000540

central nervous system development GO:0007417 regulation of synaptic plasticity GO:0048167

Downstream

Intellectual Disability Neurodevelopmental circuit dysfunction impairs intellectual and adaptive functioning.

Autism Spectrum Disorder Altered circuit development contributes to autistic behavior and social communication deficits.

Hyperactivity Circuit-level dysfunction contributes to attention problems and hyperactive behavior.

Anxiety Circuit-level dysfunction contributes to anxiety, shyness, and related social-avoidance behavior in fragile X syndrome.

Moderate Intellectual Disability Moderate intellectual disability is one severity of the cognitive impairment arising from FMRP-dependent circuit dysfunction; the determinants of individual severity remain incompletely resolved.

Show evidence (1 reference)

PMID:22483044 SUPPORT Human Clinical

"Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein)."

This ties the neurodevelopmental phenotypes to FMR1 silencing and FMRP loss.

Neuronal hyperexcitability

A subset of individuals with fragile X syndrome develop seizures. FMRP deficiency is proposed to increase neuronal excitability and susceptibility to epilepsy, often with childhood-onset focal seizure patterns.

neuron CL:0000540

Downstream

Seizures Increased neuronal excitability increases susceptibility to epilepsy and seizure manifestations.

Show evidence (2 references)

PMID:12418611 SUPPORT Human Clinical

"Deficiency of FMRP (fragile X mental retardation protein) appears to lead to increased neuronal excitability and susceptibility to epilepsy, but particularly seems to facilitate mechanisms leading to the BFEC pattern."

This clinical review explicitly connects FMRP deficiency to neuronal excitability and epilepsy susceptibility in fragile X syndrome.

PMID:31880363 SUPPORT In Vitro

"Our data demonstrate that restoration of greater than 5% of overall FMRP expression levels or greater than 20% FMRP-expressing neurons in a mosaic pattern is sufficient to normalize a FMRP-dependent, hyperactive phenotype in FXS iPSC-derived neurons."

Titrating FMRP back into patient-derived excitatory neurons shows the hyperactive phenotype at this node is FMRP dependent and reversible, and sets a low restoration threshold (above 5% of normal FMRP, or above 20% of neurons expressing it) for correcting it in that model system.

Astrocytic GABA transport dysregulation

FMRP is lost in astrocytes as well as neurons. Human FXS iPSC-derived and mouse Fmr1 knockout astrocytes accumulate GABA and the GABA-synthesizing enzymes GAD65/67, and deleting Fmr1 in astrocytes alone reduces inhibitory connectivity and degrades the fidelity of cortical temporal processing. This is a non-neuronal effector arm of FMRP loss that the synaptic translation branch does not cover. Blocking astrocytic GABA transport in the conditional knockout restores parvalbumin expression, EEG responses and exploratory behavior, which is what makes this a mechanism rather than a correlation. Evidence is currently one conditional-knockout study with a human cellular arm, so the node is model derived and awaits replication.

astrocyte CL:0000127

gamma-aminobutyric acid transport GO:0015812 ↕ DYSREGULATED

Downstream

Neuronal hyperexcitability Abnormal astrocytic GABA handling lowers cortical inhibition and tips the excitatory/inhibitory balance toward excitation.

Neurodevelopmental circuit dysfunction Loss of astrocytic control over inhibition degrades cortical temporal processing and produces abnormal exploratory behavior in astrocyte-specific knockout mice.

Show evidence (3 references)

PMID:41443375 SUPPORT Model Organism

"Our astrocyte-specific Fmr1 KO (cKO) mouse model reveals reduced inhibitory connectivity and impaired cortical responses to sound."

Restricting the Fmr1 deletion to astrocytes still produces the inhibitory and cortical-processing deficit, establishing that this arm does not require neuronal FMRP loss.

PMID:41443375 SUPPORT Model Organism

"Blocking astrocyte GABA transport enables higher PV expression, improves EEG responses to frequency-modulated sound, and corrects aberrant exploratory behavior."

The rescue arm identifies astrocytic GABA transport specifically, rather than astrocyte dysfunction generally, as the step that carries the circuit-level and behavioral consequences.

PMID:41443375 SUPPORT In Vitro

"Human FXS astrocytes derived from patient-specific induced pluripotent stem cells and mouse Fmr1 knockout (KO) astrocytes display a significant increase in levels of GABA and GABA-synthesizing enzyme GAD65/67."

The cell-culture arm shows the same GABA and GAD65/67 elevation in patient-derived human astrocytes as in mouse, which is the only human evidence currently attached to this node.

Excess translation of chromatin regulators

Most characterized FMRP targets encode synaptic proteins, but FMRP also represses transcripts encoding transcriptional and chromatin-associated regulators, among them the BET protein BRD4. Losing that repression produces widespread chromatin misregulation and aberrant gene expression, and BET inhibition reverses several fragile X phenotypes in mice. This arm runs in parallel to the synaptic translation branch and is the best pharmacologically supported of the non-synaptic effector arms, but the evidence is currently mouse based and the intermediates between chromatin misregulation and circuit dysfunction are unresolved.

translation GO:0006412 ↑ INCREASED chromatin remodeling GO:0006338 ↕ DYSREGULATED

Downstream

Neurodevelopmental circuit dysfunction Aberrant chromatin-driven gene expression contributes to the neurodevelopmental phenotype, but the steps between chromatin misregulation and circuit-level dysfunction have not been mapped.

Show evidence (2 references)

PMID:28823556 SUPPORT Model Organism

"Loss of FMRP in mice results in widespread changes in chromatin regulation and aberrant gene expression."

Establishes the chromatin consequence of FMRP loss as a distinct outcome from the synaptic one, arising from a different set of FMRP target transcripts.

PMID:28823556 SUPPORT Model Organism

"Inhibition of Brd4 function alleviated many of the phenotypes associated with FXS."

Pharmacological reversal through a chromatin reader, rather than through the mGluR pathway, is what supports treating this as a causal arm rather than an incidental transcriptional signature.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

34

Cardiovascular 2

Mitral Valve Prolapse HP:0001634

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"Recurrent findings are aortic root dilatation (approximately 25% of the patients) and mitral valve prolapse (3 –50%)"

This review identifies mitral valve prolapse (with aortic root dilatation) as the recurrent connective-tissue cardiac finding in fragile X syndrome.

Aortic Root Dilatation Aortic root aneurysm HP:0002616

Show evidence (1 reference)

PMID:20301558 SUPPORT Other

"Adults may have mitral valve prolapse or aortic root dilatation."

This sentence is in the full-mutation FXS clinical-characteristics section, before the separate FXTAS description.

Digestive 1

Gastroesophageal Reflux HP:0002020

Show evidence (1 reference)

PMID:20301558 SUPPORT Other

"Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media."

GeneReviews lists gastroesophageal reflux as a recognized medical problem in FXS.

Ear 4

Large Ears FREQUENT Macrotia HP:0000400

Show evidence (2 references)

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

The review explicitly describes large ears; protrusion is represented separately.

ORPHA:908 SUPPORT Other

"HP:0000400 | Macrotia | Frequent (79-30%)"

Orphanet's curated HPO table classifies macrotia, the HPO term used here, as frequent in Fragile X syndrome.

Chronic Otitis Media VERY_FREQUENT HP:0000389

Sequelae: Conductive Hearing Impairment

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0000389 | Chronic otitis media | Very frequent (99-80%)"

Orphanet's curated HPO table classifies chronic otitis media as very frequent in Fragile X syndrome.

Protruding Ears HP:0000411

Show evidence (1 reference)

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

The review explicitly describes protruding ears as part of the physical phenotype.

Conductive Hearing Impairment HP:0000405

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"FXS children tend to have recurrent otitis media, which may lead to conductive hearing loss [6, 8, 9, 11]."

The review explicitly describes conductive hearing loss as a complication of otitis media.

Eye 1

Strabismus HP:0000486

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"Strabismus and refractive errors have a higher prevalence in FXS than in the general population"

This review supports strabismus as an ocular manifestation enriched in fragile X syndrome relative to the general population.

Genitourinary 1

Macroorchidism HP:0000053

Orphanet records a very frequent band, applicable especially to adolescent/adult males; the cited prepubertal series found macroorchidism in only 1/27 boys aged 2.2-7 years and 7/9 aged 8-10 years. A single all-age frequency is not assigned.

Show evidence (3 references)

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

This clinical review identifies macroorchidism as part of the fragile X physical phenotype.

PMID:8190590 SUPPORT Human Clinical

"These findings suggest that macroorchidism occurs in some prepubertal boys with fragile X, but in this series it did not occur until age 6 and usually did not occur until after age 8."

The clinical series demonstrates age-dependent expression; this result does not support a very frequent band across all ages.

ORPHA:908 SUPPORT Other

"HP:0000053 | Macroorchidism | Very frequent (99-80%)"

Orphanet's curated HPO table classifies macroorchidism as very frequent in Fragile X syndrome.

Head and Neck 4

Elongated Face FREQUENT Long face HP:0000276

Show evidence (3 references)

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

This directly supports long face as part of the fragile X physical phenotype.

PMID:8237919 SUPPORT Human Clinical

"The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females."

This supports long face across affected males and females.

ORPHA:908 SUPPORT Other

"HP:0000276 | Long face | Frequent (79-30%)"

Orphanet's curated HPO table classifies long face as frequent in Fragile X syndrome.

Macrocephaly HP:0000256

Ciaccio et al. (PMID:28420439) report 81% in a male clinical-features table but describe head circumference above the 50th percentile in the text. That threshold is not diagnostic of macrocephaly or relative macrocephaly; the table percentage is not propagated as a disease-wide band.

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0000256 | Macrocephaly | Frequent (79-30%)"

Orphanet explicitly annotates macrocephaly in fragile X syndrome.

High Palate VERY_FREQUENT HP:0000218

The frequency band comes from the cited review table of clinical features in FXS males; it is not an estimate for affected females.

Show evidence (2 references)

PMID:28420439 SUPPORT Human Clinical

"Skel- etal signs may include a high-arched palate, scoliosis, pectus excavatum, and flat feet [6, 9, 24, 39, 40]."

This review lists a high-arched palate among the skeletal/connective-tissue signs of fragile X syndrome.

PMID:28420439 SUPPORT Human Clinical

"High-arched palate 94%"

The review's clinical-features table reports a high-arched palate in 94% of FXS males, supporting a very frequent band.

Mandibular Prognathia VERY_FREQUENT HP:0000303

The frequency band comes from the cited review table of clinical features in FXS males; it is not an estimate for affected females.

Show evidence (2 references)

PMID:28420439 SUPPORT Human Clinical

"Other reported facial features are the prominence of the jaw, a high-arched palate, puffiness around the eyes, long palpebral fissures, closely spaced eyes, epicanthal folds, strabismus, flat nasal bridge, broad nose, broad philtrum, and facial hypotonia (demonstrated by slackness of the lower jaw)"

This review lists prominence of the jaw among the facial features of fragile X syndrome.

PMID:28420439 SUPPORT Human Clinical

"Prominent jaw 80%"

The review's clinical-features table reports a prominent jaw in 80% of FXS males, supporting a very frequent band.

Limbs 1

Pes Planus HP:0001763

Orphanet assigns a very frequent band, whereas the male clinical-features table in Ciaccio et al. (PMID:28420439) reports flat feet in 29-69%. No single band is assigned across these differing sources.

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0001763 | Pes planus | Very frequent (99-80%)"

Orphanet's curated HPO table classifies pes planus as very frequent in Fragile X syndrome.

Musculoskeletal 4

Hypotonia FREQUENT HP:0001252

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0001252 | Hypotonia | Frequent (79-30%)"

Orphanet's curated HPO table classifies hypotonia as frequent in Fragile X syndrome.

Joint Hypermobility HP:0001382

Orphanet assigns a very frequent band, whereas Ciaccio et al. (PMID:28420439) describe joint hypermobility in about half of patients. No single band is assigned across these differing sources.

Show evidence (2 references)

PMID:8237919 SUPPORT Human Clinical

"The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females."

This directly supports hyperextensible joints as part of the fragile X physical phenotype.

ORPHA:908 SUPPORT Other

"HP:0001382 | Joint hypermobility | Very frequent (99-80%)"

Orphanet's curated HPO table classifies joint hypermobility as very frequent in Fragile X syndrome.

Pectus Excavatum FREQUENT HP:0000767

The frequency band comes from the cited review table of clinical features in FXS males; it is not an estimate for affected females.

Show evidence (2 references)

PMID:28420439 SUPPORT Human Clinical

"Skel- etal signs may include a high-arched palate, scoliosis, pectus excavatum, and flat feet [6, 9, 24, 39, 40]."

This review lists pectus excavatum among the skeletal signs of fragile X syndrome.

PMID:28420439 SUPPORT Human Clinical

"Pectus excavatum 50%"

The review's clinical-features table reports pectus excavatum in 50% of FXS males, supporting a frequent band.

Scoliosis HP:0002650

Show evidence (1 reference)

PMID:20301558 SUPPORT Other

"Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media."

GeneReviews lists scoliosis among medical manifestations of full-mutation FXS.

Nervous System 15

Sleep Disturbance HP:0002360

Show evidence (1 reference)

PMID:20301558 SUPPORT Other

"Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media."

GeneReviews lists sleep disorders as a recognized medical problem in FXS.

Intellectual Disability HP:0001249

Show evidence (1 reference)

PMID:22483044 SUPPORT Human Clinical

"Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein)."

This supports intellectual disability as a core fragile X manifestation linked to FMR1 silencing and FMRP loss.

Moderate Intellectual Disability HP:0002342

Orphanet assigns a very frequent band to moderate intellectual disability. Clinical sources describe a wide spectrum from normal-range intelligence to severe disability, especially across sexes; a disease-wide moderate-only frequency is not assigned.

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0002342 | Intellectual disability, moderate | Very frequent (99-80%)"

Orphanet's curated HPO table classifies moderate intellectual disability as very frequent in Fragile X syndrome.

Autism Spectrum Disorder HP:0000717

Show evidence (2 references)

PMID:22974167 SUPPORT Human Clinical

"Fragile X syndrome (FXS) is the leading genetic cause of autism, accounting for approximately 5% of autism cases with as many as 50% of individuals with FXS meeting DSM-IV-TR criteria for autistic disorder."

This review supports autism as a frequent comorbid neurodevelopmental phenotype in fragile X syndrome.

PMID:22483044 SUPPORT Human Clinical

"Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein)."

This supports the FMR1/FMRP mechanistic link to autism-related features.

Hyperactivity HP:0000752

Show evidence (2 references)

PMID:14730483 SUPPORT Human Clinical

"The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness."

This clinical comparison identifies hyperactivity among characteristic fragile X behavioral features.

PMID:24352914 SUPPORT Human Clinical

"Measures of anxiety, attention, and hyperactivity were highly associated with behavior problems, suggesting that these factors at least coincide with problem behavior."

This full-mutation fragile X caregiver study supports hyperactivity as a clinically measured behavioral dimension in fragile X syndrome.

Attention Deficit Hyperactivity Disorder HP:0007018

Orphanet assigns a frequent band. Ciaccio et al. (PMID:28420439) distinguish ADHD-spectrum symptoms from fulfillment of complete diagnostic criteria and report differing estimates; the frequency of symptoms is not transferred to the diagnosis.

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0007018 | Attention deficit hyperactivity disorder | Frequent (79-30%)"

Orphanet's curated HPO table classifies attention deficit hyperactivity disorder as frequent in Fragile X syndrome.

Anxiety HP:0000739

The Orphanet occasional band differs from clinical diagnostic studies. Parent-report ascertainment, age, diagnostic criteria, and the distinction between anxiety symptoms and specific anxiety disorders limit direct comparison.

Show evidence (2 references)

PMID:14730483 SUPPORT Human Clinical

"The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness."

This clinical comparison identifies anxiety as a characteristic fragile X behavioral feature linked to the genetic disorder.

PMID:21475730 SUPPORT Human Clinical

"Despite a high rate of psychopharmacological treatment, 86.2% of males and 76.9% of females met criteria for an anxiety disorder, with social phobia and specific phobia the most commonly diagnosed."

The primary full-mutation FXS study demonstrates common anxiety disorders in both sexes, inconsistent with representing anxiety simply as occasional. Estimates are from parent interviews in this cohort and are not pooled into a disease-wide band.

Seizures OCCASIONAL HP:0001250

Show evidence (2 references)

PMID:12418611 SUPPORT Human Clinical

"Seizures occurred in 15 males (13.3%) and one female (4.8%): of these, 12 had partial seizures."

This cohort supports seizures as a recurrent neurological manifestation of fragile X syndrome.

ORPHA:908 SUPPORT Other

"HP:0001250 | Seizure | Occasional (29-5%)"

Orphanet's curated HPO table classifies seizures as occasional in Fragile X syndrome.

Delayed Speech and Language Development FREQUENT HP:0000750

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0000750 | Delayed speech and language development | Frequent (79-30%)"

Orphanet's curated HPO table classifies delayed speech and language development as frequent in Fragile X syndrome.

Abnormal Speech Pattern VERY_FREQUENT HP:0002167

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0002167 | Abnormality of speech or vocalization | Very frequent (99-80%)"

Orphanet's curated HPO table classifies abnormality of speech or vocalization as very frequent in Fragile X syndrome.

Aggressive Behavior VERY_FREQUENT HP:0000718

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"This latter as- pect has been fully examined recently by Wheeler et al., who demonstrate that 90% of individuals with FXS, both males and females, were reported to be engaged in at least one aggressive act in the previous 12 months [37]."

This review reports that 90% of individuals with fragile X syndrome engaged in at least one aggressive act in the prior year, supporting a very frequent band.

Delayed Gross Motor Development HP:0002194

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"The psychomotor delay involves both walking age (mean = 2,12 years) and age at first words (mean = 2,43 years) [11]."

The review reports delayed walking and first words; this supports gross motor delay without assigning a language-plus-motor denominator to either component.

Recurrent Hand Flapping HP:0100023

Show evidence (1 reference)

PMID:14730483 SUPPORT Human Clinical

"The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness."

The human clinical comparison explicitly describes stereotypical hand flapping.

Self-injurious Behavior HP:0100716

Show evidence (1 reference)

PMID:24346713 SUPPORT Human Clinical

"FXS is characterized by mild to severe intellectual disability, susceptibility to seizures, hyperactivity, hypersensitivity to sensory stimuli, and autistic traits such as social anxiety, attention deficit, hand biting or flapping (repetitive behavior), and poor eye contact."

The human phenotype overview describes hand biting before discussing animal-model recapitulation.

EEG with Centrotemporal Epileptiform Discharges HP:0033721

Show evidence (1 reference)

PMID:12418611 SUPPORT Human Clinical

"EEG findings were available for 35 individuals (13 of 16 with seizures and 22 of 120 without seizures) and showed an epileptiform abnormality in 10 (77%) individuals with seizures and five (23%) individuals without seizures--the most common epileptiform pattern being centrotemporal spikes."

The primary clinical series supports the specific EEG pattern and separates the seizure and non-seizure subgroups. The quoted subgroup percentages apply to any epileptiform abnormality, not specifically centrotemporal spikes.

Growth 1

Obesity HP:0001513

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"Metabolic problems are common and well reported, with obesity and overweight being quite frequent in both sexes [6, 8, 42]."

The review supports occurrence of obesity. Its combined obesity/overweight percentages cannot be assigned to obesity alone.

🧬

Genetic Associations

1

FMR1 (Causative full-mutation CGG repeat expansion)

Gene: FMR1 hgnc:3775 gene page relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (3 references)

PMID:28420439 SUPPORT Human Clinical

"It is caused by an alteration of the FMR1 gene, which maps at the Xq27.3 band: more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS."

This review supports FMR1 as the causal gene and identifies full-mutation CGG repeat expansion as the dominant pathogenic variant class.

PMID:24346713 SUPPORT Other

"Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 (FMR1) gene."

This supports the causal FMR1 gene-disease relationship.

CGGV:assertion_e491d278-7123-434c-8de3-46e16afb4037-2019-06-03T160000.000Z SUPPORT Other

ClinGen classifies the FMR1-fragile X syndrome gene-disease relationship as definitive with X-linked inheritance.

Variants (1)

FMR1 full-mutation CGG repeat expansion Pathogenic

Gene: FMR1 hgnc:3775 trinucleotide repeat expansion

Pathogenic expansion of the FMR1 5' UTR CGG repeat above 200 repeats, associated with methylation-mediated loss of FMR1 expression and FMRP.

Functional effects

FMR1 expression LOE PROMOTER

Repeat expansion and methylation abolish or markedly reduce FMR1 expression across affected tissues.

🗃️

External Assertions

1

Orphanet Fragile X syndrome record

Orphanet structured disease record ORPHA:908

Orphanet curates ORPHA:908 as the Fragile X syndrome structured disease record and provides exact cross-references to MONDO, ICD-10, ICD-11, MeSH, MedDRA, UMLS, and other identifiers.

Show evidence (5 references)

ORPHA:908 SUPPORT Other

"ORPHA:908 Fragile X syndrome"

The Orphanet structured record heading identifies ORPHA:908 as the Fragile X syndrome disease record.

ORPHA:908 SUPPORT Other

"MONDO:0010383 | Exact"

Orphanet maps ORPHA:908 exactly to the same MONDO disease identifier used as this entry's disease term.

ORPHA:908 SUPPORT Other

"ICD-10:Q99.2 | Exact"

Orphanet provides an exact ICD-10 cross-reference for Fragile X syndrome.

+ 2 more references

💊

Medical Actions

8

Behavioral Therapy

Action: applied behavior analysis therapy Ontology label: Behavioral Intervention NCIT:C15184

Applied behavior analysis and educational interventions for cognitive and behavioral symptoms.

Speech Therapy

Action: speech therapy Ontology label: Speech Language Therapy NCIT:C159273

Platform: Behavioral / lifestyle

Language and communication support.

Stimulant Medications

Action: Pharmacotherapy NCIT:C15986

Agent: CNS Stimulant NCIT:C47795

For attention deficit and hyperactivity symptoms.

Mechanism Target:

MODULATES Neurodevelopmental circuit dysfunction — CNS stimulants enhance dopaminergic and noradrenergic signaling in prefrontal circuits, partially compensating for FMRP-loss-driven synaptic dysfunction underlying attention deficit and hyperactivity.

SSRIs

Action: Pharmacotherapy NCIT:C15986

Agent: Selective Serotonin Reuptake Inhibitor NCIT:C94725

For anxiety and mood symptoms.

Mechanism Target:

MODULATES Neurodevelopmental circuit dysfunction — SSRIs modulate serotonergic signaling in amygdalar and prefrontal circuits, addressing anxiety and mood dysregulation that arises downstream of FMRP-loss synaptic protein synthesis imbalance.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Family screening for FMR1 expansion carriers, prenatal testing options.

Alpha-Adrenergic Agonists

Action: Pharmacotherapy NCIT:C15986

Agent: Alpha-Adrenergic Agonist NCIT:C29709

Alpha-adrenergic agonists (e.g., clonidine, guanfacine) for hyperactivity and hyperarousal.

Mechanism Target:

MODULATES Neurodevelopmental circuit dysfunction — Alpha-adrenergic agonists dampen noradrenergic hyperarousal, addressing hyperactivity and overarousal in fragile X syndrome.

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"alpha-agonists for hyperactivity and overarousal"

This review lists alpha-agonists as pharmacotherapy for hyperactivity and overarousal in fragile X syndrome.

Antipsychotics

Action: Pharmacotherapy NCIT:C15986

Agent: Antipsychotic Agent NCIT:C29710

Atypical antipsychotics for irritability and aggressive behavior.

Mechanism Target:

MODULATES Neurodevelopmental circuit dysfunction — Antipsychotics target irritability and aggression, common behavioral challenges in fragile X syndrome.

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"In approximately 60% of pa- tients, drug treatment for psychological issues helped the remission of some symptoms; in particular, stimu- lants can be used to improve attention and hyperactivity, SSRIs for anxiety, alpha-agonists for hyperactivity and overarousal, and antipsychotics for irritable..."

This review lists antipsychotics as pharmacotherapy for irritable and aggressive behavior in fragile X syndrome.

Minocycline

Action: Pharmacotherapy NCIT:C15986

Agent: minocycline CHEBI:50694

Platform: Small molecule

Minocycline, a matrix metalloproteinase-9 inhibitor under investigation for fragile X syndrome, with reported benefit especially in young children.

Mechanism Target:

MODULATES Dendritic spine and synapse maturation abnormality — Minocycline inhibits matrix metalloproteinase-9 (elevated with FMRP loss) and is reported to strengthen synaptic connections in young children with fragile X syndrome.

Show evidence (1 reference)

PMID:28420439 SUPPORT Human Clinical

"It is currently under study for FXS treatment and seems to have its greatest effect in young children, where it strengthens synaptic connections and enhances cognitive"

This review describes minocycline as under study for fragile X syndrome with the greatest reported effect in young children.

🔬

Biochemical Markers

1

FMRP (Absent or reduced)

Context: Absent in full-mutation males; variably reduced in females and mosaic individuals.

Show evidence (1 reference)

PMID:27713816 SUPPORT In Vitro

"Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory."

This supports FMRP loss as the biochemical consequence of full-mutation FMR1 silencing.

📈

Progression

1

Onset

Age: Neonatal to childhood

Orphanet lists neonatal, infancy, and childhood onset categories for Fragile X syndrome.

Show evidence (3 references)

ORPHA:908 SUPPORT Other

"Age of onset: Neonatal"

Orphanet records neonatal onset as one natural-history category for Fragile X syndrome.

ORPHA:908 SUPPORT Other

"Age of onset: Infancy"

Orphanet records infantile onset as one natural-history category for Fragile X syndrome.

ORPHA:908 SUPPORT Other

"Age of onset: Childhood"

Orphanet records childhood onset as one natural-history category for Fragile X syndrome.

📊

Prevalence

2

General population

Point Prevalence 14.0 per 100,000 1–9 per 10,000

Meta-analysis estimates the full FMR1 mutation frequency at about 1 in 7,143 males and 1 in 11,111 females in the total population.

Show evidence (2 references)

PMID:24700618 SUPPORT Human Clinical

"Using the random-effects model, frequency of the full mutation was 1.4 (95% CI: 0.1-3.1) per 10,000 males and 0.9 (95% CI: 0.0-2.9) per 10,000 females (1:7,143 and 1:11,111, respectively) in the total population."

This systematic review and meta-analysis provides pooled sex-specific full-mutation frequencies for fragile X syndrome.

PMID:9032640 SUPPORT Human Clinical

"Revised prevalence figures have been calculated giving rise to an overall prevalence figure of 1/2720 (range 1/2198-1/3089). If the four children lost to follow up are also assumed not to have the fragile X syndrome, the revised prevalence figure was 1/5714 (range 1/4762-1/6349)."

This molecular re-evaluation of an older population cohort supports that fragile X syndrome prevalence is lower than earlier historical estimates and within the rare-disease range.

Worldwide (Orphanet point prevalence)

Point Prevalence 10.0–50.0 per 100,000 1–9 per 10,000

Orphanet reports a worldwide point-prevalence class of 1-5 per 10,000.

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"1-5 / 10 000 | Worldwide | Point prevalence | PMID:18413371,EXPERT"

The Orphanet epidemiology table provides a worldwide point-prevalence class for Fragile X syndrome.

📊

Related Datasets

6

Metabolic Reprogramming during Human Neuron Differentiation Identifies Glutaminase as a Key Determinant in Fragile X Syndrome geo:GSE296077

Metabolic homeostasis gone awry is a contributor to, if not an underlying cause of, several neurologic disorders. Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by a trinucleotide repeat expansion in FMR1 and consequent loss of the encoded protein FMRP, which results in downstream molecular, neurologic, and mitochondrial deficits that are linked to cognitive impairment. In human postmortem brain, many metabolites and solute carrier proteins are coordinately dysregulated, which also occurs during differentiation of human iPSCs into excitatory neurons.

human BULK RNA SEQ n=10

PMID:41557506

Identified by GEO DataSets index search for Fragile X Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Fragile X Syndrome Patient–Derived Neurons Developing in the Mouse Brain Show FMR1-Dependent Phenotypes geo:GSE202895

human BULK RNA SEQ n=8

PMID:36372569

Identified by GEO DataSets index search for Fragile X Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Antisense Oligonucleotide Rescue of CGG Expansion-Dependent FMR1 Mis-Splicing in Fragile X Syndrome Restores FMRP geo:GSE202179

human MULTI OMICS n=57

PMID:37364131

Identified by GEO DataSets index search for Fragile X Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Transcriptomic profiling of fragile X syndrome unmethylated full mutation carriers ega:EGAS50000000647

Total RNA sequencing of fibroblasts from two unrelated FMR1 unmethylated full mutation carriers, a fragile X patient and a control individual. The existence of rare, unmethylated full mutation carriers who carry the mutation that causes fragile X syndrome but do not gain methylation at the locus offers a rare opportunity to study the mechanisms underlying fragile X syndrome. This study aims to compare the transcriptomes of these four individuals in order to elucidate the mechanism behind the methylation a the FMR1 CGG repeat expansion that causes Fragile X syndrome.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Fragile X Syndrome"); description-level mentions were not accepted. EGA study_type: RNASeq. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Genomic profiling of fragile X syndrome unmethylated full mutation carriers ega:EGAS50000000648

Whole genome sequencing of two unrelated FMR1 unmethylated full mutation carriers. The existence of rare, unmethylated full mutation carriers who carry the mutation that causes fragile X syndrome but do not gain methylation at the locus offers a rare opportunity to study the mechanisms underlying fragile X syndrome. This study aims to investigate the genomic variants in these individuals alongside transcriptomic data to elucidate underlying genomic variants behind transcriptomic differences observed in UFM individuals.

human WGS

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Fragile X Syndrome"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

De Novo Proteome in Fragile X Syndrome massive:MSV000081061

Elevated translation has been reported in multiple models of fragile X syndrome (FXS) and in FXS individuals, however, whether it is limited to fragile X mental retardation protein (FMRP) target mRNAs or neuronal activity-derived conditions remains unclear. We examined this question by measuring the de novo proteome of the Fmr1 knockout (KO) mouse hippocampus compared to normal littermates in steady-state and mGluR-stimulated conditions.

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Fragile X Syndrome"). Retrieved 2026-08-02.

🔬

Clinical Trials

2

NCT02920892 PHASE_III COMPLETED

FXLEARN phase 3 randomized trial of AFQ056/mavoglurant for language learning in young children with fragile X syndrome; the published trial did not show significant benefit over placebo on the primary WCS language outcome.

Target Phenotypes: Delayed speech and language development HP:0000750

Show evidence (2 references)

clinicaltrials:NCT02920892 SUPPORT Human Clinical

"The purpose of this clinical trial is to investigate the impact of AFQ056 on language learning in 3-6 year old children with Fragile X Syndrome (FXS)."

ClinicalTrials.gov documents the AFQ056 language-learning trial in young children with fragile X syndrome.

PMID:37651202 SUPPORT Human Clinical

"Although both groups made language progress and there were no safety issues, the change in WCS score during the placebo-controlled period was not significantly different between the AFQ056 and placebo-treated groups, nor were there any significant between-group differences in change in any..."

The published FXLEARN report supports the completed phase 3 trial and its negative primary and secondary efficacy results.

NCT03569631 PHASE_II COMPLETED

Phase 2a randomized double-blind crossover trial of BPN14770/zatolmilast in adult males with fragile X syndrome, with published cognition, language, daily-functioning, and EEG biomarker analyses.

Target Phenotypes: Intellectual disability HP:0001249

Show evidence (2 references)

clinicaltrials:NCT03569631 SUPPORT Human Clinical

"This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome."

ClinicalTrials.gov documents the BPN14770 crossover trial in adult males with fragile X syndrome.

DOI:10.1186/s13229-024-00626-0 SUPPORT Human Clinical

"A recent phase 2a clinical trial testing BPN14770, a phosphodiesterase 4D inhibitor, showed improved cognition in 30 adult males with FXS on drug relative to placebo."

The Molecular Autism biomarker analysis supports the phase 2a BPN14770 trial and its reported cognition signal.

{ }

Source YAML

click to show

name: Fragile X Syndrome
creation_date: '2026-01-07T17:31:51Z'
description: >-
  Fragile X syndrome is the most common inherited cause of intellectual disability and a leading
  monogenic cause of autism. It results from expansion of a CGG trinucleotide repeat in the 5'
  untranslated region of the FMR1 gene; full mutations (>200 repeats) trigger promoter
  hypermethylation and transcriptional silencing, abolishing the fragile X messenger
  ribonucleoprotein (FMRP). Loss of FMRP dysregulates synaptic protein translation, contributing to
  intellectual disability and behavioral abnormalities. Characteristic physical features also occur,
  with less completely resolved tissue mechanisms.
category: Genetic
parents:
- Intellectual Disability Syndrome
- Trinucleotide Repeat Disorder
disease_term:
  preferred_term: fragile X syndrome
  term:
    id: MONDO:0010383
    label: fragile X syndrome
gene_sets:
- gene_set: MYGENESET:WP_FRAGILE_X_SYNDROME
  relationship: CANONICAL_PATHWAY
  note: >-
    WikiPathways fragile X syndrome pathway.
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:Q99.2
      label: Fragile X chromosome
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:908
    mapping_justification: Orphanet lists ICD-10 Q99.2 as an exact cross-reference for fragile X syndrome.
    consistency:
    - reference: ORPHA:908
      consistent: CONSISTENT
      notes: "ICD-10:Q99.2 | Exact"
  icd11f_mappings:
  - term:
      id: icd11f:1524287677
      label: Fragile X chromosome
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:908
    mapping_justification: >-
      Orphanet lists ICD-11 LD55 as an exact cross-reference; the local
      ICD-11 Foundation ontology represents this as icd11f:1524287677.
    consistency:
    - reference: ORPHA:908
      consistent: CONSISTENT
      notes: "ICD-11:LD55 | Exact"
  mondo_mappings:
  - term:
      id: MONDO:0010383
      label: fragile X syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:908
    mapping_justification: Orphanet lists MONDO:0010383 as an exact cross-reference for fragile X syndrome.
    consistency:
    - reference: ORPHA:908
      consistent: CONSISTENT
      notes: "MONDO:0010383 | Exact"
external_assertions:
- name: Orphanet Fragile X syndrome record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:908
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=908
  description: >-
    Orphanet curates ORPHA:908 as the Fragile X syndrome structured disease
    record and provides exact cross-references to MONDO, ICD-10, ICD-11, MeSH,
    MedDRA, UMLS, and other identifiers.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:908  Fragile X syndrome"
    explanation: The Orphanet structured record heading identifies ORPHA:908 as the Fragile X syndrome disease record.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0010383 | Exact"
    explanation: Orphanet maps ORPHA:908 exactly to the same MONDO disease identifier used as this entry's disease term.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:Q99.2 | Exact"
    explanation: Orphanet provides an exact ICD-10 cross-reference for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:LD55 | Exact"
    explanation: Orphanet provides an exact ICD-11 cross-reference for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UMLS:C0016667 | Exact"
    explanation: Orphanet provides an exact UMLS cross-reference for Fragile X syndrome.
has_subtypes:
- name: Full Mutation
  description: More than 200 CGG repeats with methylation, full syndrome expression in males.
inheritance:
- name: X-linked dominant inheritance
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
  description: >-
    Orphanet classifies fragile X syndrome as X-linked dominant; clinical
    expression is typically more severe in affected males and variable in
    heterozygous females.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "X-linked dominant"
    explanation: Orphanet directly lists X-linked dominant inheritance for Fragile X syndrome.
prevalence:
- population: General population
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 14.0
  percentage: 1.4 per 10,000 males; 0.9 per 10,000 females
  notes: >-
    Meta-analysis estimates the full FMR1 mutation frequency at about 1 in
    7,143 males and 1 in 11,111 females in the total population.
  evidence:
  - reference: PMID:24700618
    reference_title: "Epidemiology of fragile X syndrome: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using the random-effects model, frequency of the full mutation was 1.4 (95% CI: 0.1-3.1) per 10,000 males and 0.9 (95% CI: 0.0-2.9) per 10,000 females (1:7,143 and 1:11,111, respectively) in the total population."
    explanation: This systematic review and meta-analysis provides pooled sex-specific full-mutation frequencies for fragile X syndrome.
  - reference: PMID:9032640
    reference_title: "Fragile X syndrome is less common than previously estimated"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Revised prevalence figures have been calculated giving rise to an overall prevalence figure of 1/2720 (range 1/2198-1/3089). If the four children lost to follow up are also assumed not to have the fragile X syndrome, the revised prevalence figure was 1/5714 (range 1/4762-1/6349)."
    explanation: This molecular re-evaluation of an older population cohort supports that fragile X syndrome prevalence is lower than earlier historical estimates and within the rare-disease range.
- population: Worldwide (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: "1-5 / 10 000"
  notes: Orphanet reports a worldwide point-prevalence class of 1-5 per 10,000.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Worldwide | Point prevalence | PMID:18413371,EXPERT"
    explanation: The Orphanet epidemiology table provides a worldwide point-prevalence class for Fragile X syndrome.
progression:
- phase: Onset
  age_range: Neonatal to childhood
  notes: Orphanet lists neonatal, infancy, and childhood onset categories for Fragile X syndrome.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Neonatal"
    explanation: Orphanet records neonatal onset as one natural-history category for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet records infantile onset as one natural-history category for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet records childhood onset as one natural-history category for Fragile X syndrome.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model
  hypothesis_label: Canonical FMR1 Silencing / FMRP Loss / Synaptic Translation Dysregulation Model
  status: CANONICAL
  description: >-
    Fragile X syndrome (FXS) is caused by CGG-trinucleotide repeat expansion (>200 repeats) in the
    5' UTR of FMR1 on Xq27.3, leading to hypermethylation and transcriptional silencing of FMR1 and
    loss of its protein product FMRP. FMRP is an RNA-binding protein that represses translation of
    hundreds of synaptic mRNAs at dendrites and is required for the metabotropic glutamate receptor
    (mGluR)-dependent regulation of synaptic protein synthesis. Loss of FMRP produces excessive and
    decoupled local protein synthesis, leading to exaggerated mGluR-LTD, abnormal dendritic spine
    morphology, altered excitatory/inhibitory balance, and the cognitive and behavioral phenotypes
    of FXS. mGluR5 antagonists, GABAergic modulators, and IGF-1 / BDNF / MAPK-pathway perturbation
    studies in Fmr1-knockout mice and human iPSC-derived neurons all corroborate the canonical
    FMRP-loss / dysregulated synaptic-translation model.
  notes: >-
    Retained as CANONICAL with hub-and-spoke
    annotation. The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Fragile_X_Syndrome/canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model)
    confirms CGG-expansion → FMR1 silencing → FMRP loss as the
    central lesion, with dCas9-Tet1 demethylation rescuing FMR1
    expression and neuronal phenotypes (>5% FMRP restoration
    sufficient) providing the strongest causal proof. FMRP target
    mRNAs are enriched among de novo mutations in schizophrenia,
    autism, and intellectual disability, validating FMRP as a
    central translational regulator. Three critical refinements:
    (1) clinical translation failure — multiple Phase 2b mGluR5-antagonist
    trials failed in FXS patients, attributed by expert
    consensus to trial design but the question remains open;
    (2) mechanistic scope must expand beyond synaptic translation —
    FMRP has critical non-synaptic functions in genome stability
    (R-loop prevention), chromatin regulation (BRD4), astrocyte-autonomous
    GABA transport, and metabolic programming;
    (3) phenotypes are age- and condition-dependent — enhanced
    mGluR-LTD is restricted to the P30–60 age window in mice;
    spine density normalizes by adulthood while dendritic
    complexity progressively worsens. The report recommends
    annotating the model as a hub-and-spoke architecture in which
    FMRP loss disrupts multiple parallel effector arms, with
    synaptic translation being the best-studied but not the sole
    driver of clinical phenotypes.
  evidence:
  - reference: PMID:24346713
    reference_title: "From FMRP function to potential therapies for fragile X syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations."
    explanation: >
      Canonical mechanism reference used as the seed for the
      hypothesis-search deep-research run.
pathophysiology:
- name: Somatic CGG Repeat Expansion (FMR1)
  conforms_to: "mismatch_repair_driven_repeat_instability#Aberrant Mismatch-Repair Processing of the Repeat"
  biological_scale: TISSUE
  description: >-
    The FMR1 CGG repeat is processed by an aberrant DNA mismatch-repair route:
    the MutSβ (MSH2-MSH3) recognition complex, with the MutLγ (MLH1-MLH3)
    effector complex acting downstream, is required for germline and somatic CGG
    expansion in knock-in mouse models of the fragile X-associated disorders.
    This is the CGG-class instance of the module's aberrant-MMR machinery and
    lies upstream of the full-mutation methylation silencing that abolishes
    FMRP. Unlike the CAG/CTG disorders, ongoing post-mitotic somatic expansion is
    not established as the rate-limiting driver of fragile X syndrome onset —
    in humans the premutation to full-mutation transition is predominantly a
    maternal-germline / early-embryonic event and the silencing is already set
    developmentally — so this node conforms only at the molecular
    MMR-processing level, not at the module's somatic post-mitotic expansion
    node.
  genes:
  - preferred_term: FMR1
    term:
      id: hgnc:3775
      label: FMR1
  - preferred_term: MSH3
    term:
      id: hgnc:7326
      label: MSH3
  biological_processes:
  - preferred_term: mismatch repair
    term:
      id: GO:0006298
      label: mismatch repair
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:26420841
    reference_title: >-
      Mutsβ generates both expansions and contractions in a mouse model of the
      Fragile X-associated disorders.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      MSH3, the MSH2-binding partner in the MutSβ complex, is required for 98% of
      germ line expansions and all somatic expansions in this model.
    explanation: >-
      A Fragile X mouse model shows the MutSβ (MSH2-MSH3) complex is required for
      all somatic CGG expansion, the CGG-class instance of the module's
      aberrant-MMR mechanism.
  - reference: PMID:30312299
    reference_title: >-
      MutLγ promotes repeat expansion in a Fragile X mouse model while EXO1 is
      protective.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      MLH1/MLH3 (MutLγ), a protein complex that can act downstream of MutSβ in
      MMR, is also required for all germ line and somatic expansions.
    explanation: >-
      The same Fragile X model shows the MutLγ (MLH1-MLH3) effector complex
      acting downstream of MutSβ is required for CGG expansion, with EXO1
      protective — the machinery of the module's amplifier node.
  downstream:
  - target: FMR1 full-mutation transcriptional silencing
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Germline and early-embryonic expansion of the premutation allele past the full-mutation (>200 repeat) threshold
    description: >-
      Aberrant MMR processing of the CGG tract contributes to the expansion that
      produces the full-mutation allele, which in turn triggers promoter
      hypermethylation and transcriptional silencing of FMR1. The expansion step
      itself is omitted from this edge.
- name: FMR1 full-mutation transcriptional silencing
  description: >-
    The canonical initiating event is expansion of the FMR1 5' UTR CGG repeat
    above 200 repeats. Full-mutation alleles become epigenetically silenced in
    differentiated cells, which reduces or abolishes fragile X messenger
    ribonucleoprotein (FMRP).
  gene:
    preferred_term: FMR1
    modifier: DECREASED
    term:
      id: hgnc:3775
      label: FMR1
  downstream:
  - target: FMRP loss of translational repression
    causal_link_type: DIRECT
    description: >-
      Epigenetic silencing of the full-mutation FMR1 allele decreases FMRP,
      removing a key RNA-binding translational repressor.
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS.
    explanation: >-
      This review establishes the full-mutation CGG expansion as the dominant
      molecular diagnosis for fragile X syndrome.
  - reference: PMID:27713816
    reference_title: "CGG-repeat dynamics and FMR1 gene silencing in fragile X syndrome stem cells and stem cell-derived neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory.
    explanation: >-
      Patient-derived stem-cell and neuronal differentiation work supports
      epigenetic silencing of full-mutation alleles and consequent FMRP loss.
  - reference: PMID:29456084
    reference_title: "Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Targeted demethylation of the CGG expansion by dCas9-Tet1/single guide RNA (sgRNA) switched the heterochromatin status of the upstream FMR1 promoter to an active chromatin state, restoring a persistent expression of FMR1 in FXS iPSCs.
    explanation: >-
      Removing the methylation reactivates FMR1 and rescues the
      electrophysiological abnormality of the derived neurons, so
      methylation-dependent silencing is the operative lesion at this node
      rather than a correlate of it.
- name: FMRP loss of translational repression
  description: >-
    FMRP normally binds coding and non-coding RNAs and restrains translation at
    dendritic and synaptic locations. Loss of FMRP removes this brake, increasing
    basal protein translation and uncoupling translation from neuronal activity.
  gene:
    preferred_term: FMR1
    modifier: DECREASED
    term:
      id: hgnc:3775
      label: FMR1
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: negative regulation of translation
    term:
      id: GO:0017148
      label: negative regulation of translation
    modifier: DECREASED
  downstream:
  - target: Synaptic protein synthesis and mGluR signaling dysregulation
    causal_link_type: DIRECT
    description: >-
      Loss of FMRP increases basal translation and disrupts mGluR-triggered
      translational control at synapses.
  - target: Excess translation of chromatin regulators
    causal_link_type: DIRECT
    description: >-
      FMRP also represses transcripts encoding chromatin-associated regulators,
      so its loss lifts that brake as well as the synaptic one.
  - target: Astrocytic GABA transport dysregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Astrocytic GABA synthesis and uptake
    description: >-
      FMRP is lost in astrocytes as well as neurons, and astrocyte-restricted
      Fmr1 deletion alone is sufficient to disturb astrocytic GABA handling.
  evidence:
  - reference: PMID:24346713
    reference_title: "From FMRP function to potential therapies for fragile X syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations.
    explanation: >-
      This directly supports FMRP as a translational repressor at neuronal
      dendritic and synaptic sites.
  - reference: PMID:22483044
    reference_title: "The pathophysiology of fragile X (and what it teaches us about synapses)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      FMRP is an mRNA-binding protein that functions at many synapses to inhibit local translation stimulated by metabotropic glutamate receptors (mGluRs) 1 and 5.
    explanation: >-
      This supports the mechanism linking FMRP loss to dysregulated local
      synaptic translation.
  - reference: PMID:21784246
    reference_title: "FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We developed a brain polyribosome-programmed translation system, revealing that FMRP reversibly stalls ribosomes specifically on its target mRNAs.
    explanation: >-
      Identifies the molecular action that is lost at this node. FMRP holds
      ribosomes in a reversible stall on its own target transcripts, so removing
      it releases those transcripts specifically rather than raising translation
      indiscriminately.
  - reference: PMID:35379866
    reference_title: "Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IQ scores were positively correlated with FXP levels in males and females with full mutation FXS demonstrating the clinical utility of this method.
    explanation: >-
      Residual FMRP tracks cognitive outcome in both sexes with the full
      mutation, so the deficit at this node is graded rather than all or none.
      The measurement is peripheral (dried blood spots), not brain tissue.
- name: Synaptic protein synthesis and mGluR signaling dysregulation
  description: >-
    With FMRP absent, basal translation is enhanced and mGluR1/5-linked local
    translation is no longer appropriately regulated. This distorts the
    experience-dependent protein synthesis needed for synaptic plasticity.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of synaptic plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  downstream:
  - target: Dendritic spine and synapse maturation abnormality
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Activity-dependent translation of FMRP target RNAs
    - mGluR1/5-linked local protein synthesis
    description: >-
      Dysregulated local translation alters synaptic plasticity programs that
      shape dendritic spine and synapse maturation.
  - target: Neurodevelopmental circuit dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered synaptic protein synthesis
    - Altered synaptic plasticity
    description: >-
      Abnormal synaptic protein synthesis and plasticity impair the neural
      circuit functions required for cognition, social behavior, and attention.
  evidence:
  - reference: PMID:24346713
    reference_title: "From FMRP function to potential therapies for fragile X syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In the absence of FMRP, the basal protein translation is enhanced and not responsive to neuronal stimulation.
    explanation: >-
      This supports enhanced basal protein translation after FMRP loss.
  - reference: PMID:22483044
    reference_title: "The pathophysiology of fragile X (and what it teaches us about synapses)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Recent studies on the biology of FMRP and the signaling pathways downstream of mGluR1/5 have yielded deeper insight into how synaptic protein synthesis and plasticity are regulated by experience.
    explanation: >-
      This places mGluR1/5-linked signaling and synaptic protein synthesis
      within the fragile X pathophysiology framework.
- name: Dendritic spine and synapse maturation abnormality
  description: >-
    FMRP loss disrupts synapse structure and dendritic spine maturation.
    Patient and model-system literature consistently links fragile X syndrome
    to altered structural and functional synaptic plasticity, with cell-type and
    brain-region-specific changes in synapse density and spine morphology.
    The spine component of this node is age dependent in the mouse rather than
    static: density is raised during early development and returns to wild-type
    levels by adulthood, while dendritic branching complexity falls
    progressively with age. Curate adult structural claims accordingly.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
  - preferred_term: protein localization to synapse
    term:
      id: GO:0035418
      label: protein localization to synapse
  downstream:
  - target: Neurodevelopmental circuit dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered synapse density
    - Altered dendritic spine morphology
    description: >-
      Altered synapse and spine maturation disrupts network-level signaling
      needed for cognition and behavior.
  - target: Neuronal hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered synaptic plasticity
    - Altered excitatory and inhibitory balance
    description: >-
      Synaptic dysregulation contributes to increased neuronal excitability and
      seizure susceptibility in a subset of affected individuals.
  evidence:
  - reference: PMID:33013316
    reference_title: "The Fragile X Mental Retardation Protein Regulates Striatal Medium Spiny Neuron Synapse Density and Dendritic Spine Morphology."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Loss of FMRP, as in fragile X syndrome (FXS), is a leading monogenic cause of autism and results in altered structural and functional synaptic plasticity, widely described in the hippocampus and cortex.
    explanation: >-
      This supports altered structural and functional synaptic plasticity as a
      downstream effect of FMRP loss.
  - reference: PMID:33013316
    reference_title: "The Fragile X Mental Retardation Protein Regulates Striatal Medium Spiny Neuron Synapse Density and Dendritic Spine Morphology."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Utilizing a cortical-striatal co-culture model, we find that striatal medium spiny neurons (MSNs) lacking FMRP fail to make normal increases in PSD95 expression over a short time period and have significant deficits in dendritic spine density and colocalized synaptic puncta at the later measured time point compared to wildtype (WT) MSNs.
    explanation: >-
      This in vitro model links FMRP loss to abnormal postsynaptic marker
      expression, dendritic spine density, and synaptic puncta.
  - reference: PMID:41982083
    reference_title: "Age-Related Decline in Dendritic Architecture of Hippocampal CA1 Principal Neurons in a Mouse Model of Fragile X Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In contrast, spine density was increased in both apical and basal dendrites during early development but normalized to wild-type levels in adulthood.
    explanation: >-
      Golgi-Cox analysis across four developmental stages from P14 to P150 shows
      the raised spine density is a developmental feature that resolves, so this
      node should not be read as asserting a persistent adult spine excess.
  - reference: PMID:41982083
    reference_title: "Age-Related Decline in Dendritic Architecture of Hippocampal CA1 Principal Neurons in a Mouse Model of Fragile X Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We identified a progressive reduction in dendritic complexity, reflected by decreased Sholl intersections and reduced dendritic branch number and length.
    explanation: >-
      The same study reports the complementary half of the dissociation: while
      spine density normalizes, dendritic arbor complexity declines with age,
      which is the structural change that persists into mature circuits. Single
      unreplicated mouse study in hippocampal CA1 principal neurons.
- name: Neurodevelopmental circuit dysfunction
  description: >-
    Synaptic translation and spine abnormalities converge on disrupted neural
    circuit development and function. This branch accounts for the core
    cognitive and behavioral manifestations of fragile X syndrome, including
    intellectual disability, autistic behavior, and hyperactivity.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: central nervous system development
    term:
      id: GO:0007417
      label: central nervous system development
  - preferred_term: regulation of synaptic plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  downstream:
  - target: Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Neurodevelopmental circuit dysfunction impairs intellectual and adaptive
      functioning.
  - target: Autism Spectrum Disorder
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Altered circuit development contributes to autistic behavior and social
      communication deficits.
  - target: Hyperactivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Circuit-level dysfunction contributes to attention problems and
      hyperactive behavior.
  - target: Anxiety
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Circuit-level dysfunction contributes to anxiety, shyness, and related
      social-avoidance behavior in fragile X syndrome.
  - target: Moderate Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Moderate intellectual disability is one severity of the cognitive impairment arising from
      FMRP-dependent circuit dysfunction; the determinants of individual severity remain
      incompletely resolved.
  evidence:
  - reference: PMID:22483044
    reference_title: "The pathophysiology of fragile X (and what it teaches us about synapses)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein).
    explanation: >-
      This ties the neurodevelopmental phenotypes to FMR1 silencing and FMRP
      loss.
- name: Neuronal hyperexcitability
  description: >-
    A subset of individuals with fragile X syndrome develop seizures. FMRP
    deficiency is proposed to increase neuronal excitability and susceptibility
    to epilepsy, often with childhood-onset focal seizure patterns.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Seizures
    causal_link_type: DIRECT
    description: >-
      Increased neuronal excitability increases susceptibility to epilepsy and
      seizure manifestations.
  evidence:
  - reference: PMID:12418611
    reference_title: "Epilepsy in fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deficiency of FMRP (fragile X mental retardation protein) appears to lead to increased neuronal excitability and susceptibility to epilepsy, but particularly seems to facilitate mechanisms leading to the BFEC pattern.
    explanation: >-
      This clinical review explicitly connects FMRP deficiency to neuronal
      excitability and epilepsy susceptibility in fragile X syndrome.
  - reference: PMID:31880363
    reference_title: "Partial FMRP expression is sufficient to normalize neuronal hyperactivity in Fragile X neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Our data demonstrate that restoration of greater than 5% of overall FMRP expression levels or greater than 20% FMRP-expressing neurons in a mosaic pattern is sufficient to normalize a FMRP-dependent, hyperactive phenotype in FXS iPSC-derived neurons.
    explanation: >-
      Titrating FMRP back into patient-derived excitatory neurons shows the
      hyperactive phenotype at this node is FMRP dependent and reversible, and
      sets a low restoration threshold (above 5% of normal FMRP, or above 20% of
      neurons expressing it) for correcting it in that model system.
- name: Astrocytic GABA transport dysregulation
  biological_scale: CELLULAR
  description: >-
    FMRP is lost in astrocytes as well as neurons. Human FXS iPSC-derived and
    mouse Fmr1 knockout astrocytes accumulate GABA and the GABA-synthesizing
    enzymes GAD65/67, and deleting Fmr1 in astrocytes alone reduces inhibitory
    connectivity and degrades the fidelity of cortical temporal processing.
    This is a non-neuronal effector arm of FMRP loss that the synaptic
    translation branch does not cover. Blocking astrocytic GABA transport in the
    conditional knockout restores parvalbumin expression, EEG responses and
    exploratory behavior, which is what makes this a mechanism rather than a
    correlation. Evidence is currently one conditional-knockout study with a
    human cellular arm, so the node is model derived and awaits replication.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: gamma-aminobutyric acid transport
    term:
      id: GO:0015812
      label: gamma-aminobutyric acid transport
    modifier: DYSREGULATED
  downstream:
  - target: Neuronal hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced cortical inhibitory connectivity
    - Reduced parvalbumin interneuron activity
    description: >-
      Abnormal astrocytic GABA handling lowers cortical inhibition and tips the
      excitatory/inhibitory balance toward excitation.
  - target: Neurodevelopmental circuit dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced cortical inhibitory connectivity
    description: >-
      Loss of astrocytic control over inhibition degrades cortical temporal
      processing and produces abnormal exploratory behavior in
      astrocyte-specific knockout mice.
  evidence:
  - reference: PMID:41443375
    reference_title: "Astrocytic GABA controls fidelity of temporal cortical processing in Fragile X Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Our astrocyte-specific Fmr1 KO (cKO) mouse model reveals reduced inhibitory connectivity and impaired cortical responses to sound.
    explanation: >-
      Restricting the Fmr1 deletion to astrocytes still produces the inhibitory
      and cortical-processing deficit, establishing that this arm does not
      require neuronal FMRP loss.
  - reference: PMID:41443375
    reference_title: "Astrocytic GABA controls fidelity of temporal cortical processing in Fragile X Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Blocking astrocyte GABA transport enables higher PV expression, improves EEG responses to frequency-modulated sound, and corrects aberrant exploratory behavior.
    explanation: >-
      The rescue arm identifies astrocytic GABA transport specifically, rather
      than astrocyte dysfunction generally, as the step that carries the
      circuit-level and behavioral consequences.
  - reference: PMID:41443375
    reference_title: "Astrocytic GABA controls fidelity of temporal cortical processing in Fragile X Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Human FXS astrocytes derived from patient-specific induced pluripotent stem cells and mouse Fmr1 knockout (KO) astrocytes display a significant increase in levels of GABA and GABA-synthesizing enzyme GAD65/67.
    explanation: >-
      The cell-culture arm shows the same GABA and GAD65/67 elevation in
      patient-derived human astrocytes as in mouse, which is the only human
      evidence currently attached to this node.
- name: Excess translation of chromatin regulators
  biological_scale: MOLECULAR
  description: >-
    Most characterized FMRP targets encode synaptic proteins, but FMRP also
    represses transcripts encoding transcriptional and chromatin-associated
    regulators, among them the BET protein BRD4. Losing that repression produces
    widespread chromatin misregulation and aberrant gene expression, and BET
    inhibition reverses several fragile X phenotypes in mice. This arm runs in
    parallel to the synaptic translation branch and is the best
    pharmacologically supported of the non-synaptic effector arms, but the
    evidence is currently mouse based and the intermediates between chromatin
    misregulation and circuit dysfunction are unresolved.
  biological_processes:
  - preferred_term: translation
    term:
      id: GO:0006412
      label: translation
    modifier: INCREASED
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
    modifier: DYSREGULATED
  downstream:
  - target: Neurodevelopmental circuit dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Aberrant chromatin-driven gene expression contributes to the
      neurodevelopmental phenotype, but the steps between chromatin
      misregulation and circuit-level dysfunction have not been mapped.
  evidence:
  - reference: PMID:28823556
    reference_title: "Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Loss of FMRP in mice results in widespread changes in chromatin regulation and aberrant gene expression.
    explanation: >-
      Establishes the chromatin consequence of FMRP loss as a distinct outcome
      from the synaptic one, arising from a different set of FMRP target
      transcripts.
  - reference: PMID:28823556
    reference_title: "Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Inhibition of Brd4 function alleviated many of the phenotypes associated with FXS.
    explanation: >-
      Pharmacological reversal through a chromatin reader, rather than through
      the mGluR pathway, is what supports treating this as a causal arm rather
      than an incidental transcriptional signature.
phenotypes:
- name: Sleep Disturbance
  category: Neurological
  description: >-
    Sleep disorders are recognized in fragile X syndrome, including difficulty initiating or
    maintaining sleep. The clinical evidence here does not establish a specific GABAergic or
    circadian mechanism.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media."
    explanation: GeneReviews lists sleep disorders as a recognized medical problem in FXS.
- name: Gastroesophageal Reflux
  category: Gastrointestinal
  description: >-
    Gastroesophageal reflux is a recognized medical problem in children with
    fragile X syndrome, often presenting in infancy and early childhood.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:20301558
    reference_title: "FMR1 Disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media."
    explanation: GeneReviews lists gastroesophageal reflux as a recognized medical problem in FXS.
- name: Intellectual Disability
  category: Neurological
  diagnostic: true
  description: >-
    Intellectual disability is a cardinal neurodevelopmental manifestation of
    fragile X syndrome and is generally more severe in males with full-mutation
    FMR1 silencing.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:22483044
    reference_title: "The pathophysiology of fragile X (and what it teaches us about synapses)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein).
    explanation: >-
      This supports intellectual disability as a core fragile X manifestation
      linked to FMR1 silencing and FMRP loss.
- name: Moderate Intellectual Disability
  category: Neurological
  description: >-
    Moderate intellectual disability is one documented severity within the variable cognitive
    phenotype of fragile X syndrome.
  phenotype_term:
    preferred_term: Moderate intellectual disability
    term:
      id: HP:0002342
      label: Moderate intellectual disability
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002342 | Intellectual disability, moderate | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies moderate intellectual disability as very frequent in Fragile X syndrome.
  notes: >-
    Orphanet assigns a very frequent band to moderate intellectual disability. Clinical sources
    describe a wide spectrum from normal-range intelligence to severe disability, especially across
    sexes; a disease-wide moderate-only frequency is not assigned.
- name: Autism Spectrum Disorder
  category: Behavioral
  description: >-
    Autism spectrum disorder is diagnosed in a substantial subset of individuals with fragile X
    syndrome. Estimates depend on sex, age, ascertainment, and diagnostic criteria; autistic traits
    can also occur without meeting full diagnostic criteria.
  phenotype_term:
    preferred_term: Autism spectrum disorder
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:22974167
    reference_title: "Early identification of autism in fragile X syndrome: a review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X syndrome (FXS) is the leading genetic cause of autism, accounting for approximately 5% of autism cases with as many as 50% of individuals with FXS meeting DSM-IV-TR criteria for autistic disorder.
    explanation: >-
      This review supports autism as a frequent comorbid neurodevelopmental
      phenotype in fragile X syndrome.
  - reference: PMID:22483044
    reference_title: "The pathophysiology of fragile X (and what it teaches us about synapses)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein).
    explanation: >-
      This supports the FMR1/FMRP mechanistic link to autism-related features.
- name: Hyperactivity
  category: Behavioral
  description: >-
    Hyperactivity and attention problems are part of the fragile X behavioral
    profile and often co-occur with anxiety and other behavioral challenges.
  phenotype_term:
    preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  evidence:
  - reference: PMID:14730483
    reference_title: "[Can the behavioural phenotype of fragile X syndrome be attributed to mental retardation and to attention deficit hyperactivity disorder?]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness.
    explanation: >-
      This clinical comparison identifies hyperactivity among characteristic
      fragile X behavioral features.
  - reference: PMID:24352914
    reference_title: "Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Measures of anxiety, attention, and hyperactivity were highly associated with behavior problems, suggesting that these factors at least coincide with problem behavior.
    explanation: >-
      This full-mutation fragile X caregiver study supports hyperactivity as a
      clinically measured behavioral dimension in fragile X syndrome.
- name: Attention Deficit Hyperactivity Disorder
  category: Behavioral
  description: >-
    Attention deficit hyperactivity disorder occurs in fragile X syndrome and is clinically distinct
    from isolated hyperactivity or inattention.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007018 | Attention deficit hyperactivity disorder | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies attention deficit hyperactivity disorder as frequent in Fragile X syndrome.
  notes: >-
    Orphanet assigns a frequent band. Ciaccio et al. (PMID:28420439) distinguish ADHD-spectrum
    symptoms from fulfillment of complete diagnostic criteria and report differing estimates; the
    frequency of symptoms is not transferred to the diagnosis.
- name: Anxiety
  category: Behavioral
  description: >-
    Anxiety is a prominent behavioral feature of fragile X syndrome and may include social and
    specific phobias. One clinical series found a current anxiety disorder in 86.2% of males and
    76.9% of females aged 5-33 years.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:14730483
    reference_title: "[Can the behavioural phenotype of fragile X syndrome be attributed to mental retardation and to attention deficit hyperactivity disorder?]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most characteristic types of conduct seen in FXS include: language
      problems, lack of attention, hyperactivity, anxiety, shyness, behavioural
      problems, stereotypical hand flapping, gaze aversion, obstinacy and
      aggressiveness.
    explanation: >-
      This clinical comparison identifies anxiety as a characteristic fragile
      X behavioral feature linked to the genetic disorder.
  - reference: PMID:21475730
    reference_title: "Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite a high rate of psychopharmacological treatment, 86.2% of males and 76.9% of females met criteria for an anxiety disorder, with social phobia and specific phobia the most commonly diagnosed.
    explanation: >-
      The primary full-mutation FXS study demonstrates common anxiety disorders in both sexes,
      inconsistent with representing anxiety simply as occasional. Estimates are from parent
      interviews in this cohort and are not pooled into a disease-wide band.
  notes: >-
    The Orphanet occasional band differs from clinical diagnostic studies. Parent-report
    ascertainment, age, diagnostic criteria, and the distinction between anxiety symptoms and
    specific anxiety disorders limit direct comparison.
- name: Seizures
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Seizures occur in a minority of individuals with fragile X syndrome,
    commonly with childhood focal seizure or EEG patterns and generally
    favorable remission in reported cohorts.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:12418611
    reference_title: "Epilepsy in fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures occurred in 15 males (13.3%) and one female (4.8%): of these, 12 had partial seizures.
    explanation: >-
      This cohort supports seizures as a recurrent neurological manifestation
      of fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
    explanation: Orphanet's curated HPO table classifies seizures as occasional in Fragile X syndrome.
- name: Delayed Speech and Language Development
  category: Neurological
  frequency: FREQUENT
  description: >-
    Delayed speech and language development is part of the neurodevelopmental
    phenotype spectrum recorded for Fragile X syndrome.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000750 | Delayed speech and language development | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies delayed speech and language development as frequent in Fragile X syndrome.
- name: Abnormal Speech Pattern
  category: Neurological
  frequency: VERY_FREQUENT
  description: >-
    Abnormal speech patterns are recorded in fragile X syndrome, distinct from delayed acquisition
    of speech and language.
  phenotype_term:
    preferred_term: Abnormal speech pattern
    term:
      id: HP:0002167
      label: Abnormal speech pattern
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002167 | Abnormality of speech or vocalization | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies abnormality of speech or vocalization as very frequent in Fragile X syndrome.
- name: Hypotonia
  category: Neurological
  frequency: FREQUENT
  description: >-
    Hypotonia is a frequent motor feature in Orphanet's Fragile X syndrome HPO
    profile.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies hypotonia as frequent in Fragile X syndrome.
- name: Macroorchidism
  category: Genitourinary
  description: >-
    Macroorchidism is a characteristic male physical feature, becoming most
    apparent after later childhood and puberty.
  phenotype_term:
    preferred_term: Macroorchidism
    term:
      id: HP:0000053
      label: Macroorchidism
  evidence:
  - reference: PMID:9678703
    reference_title: "The fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      This clinical review identifies macroorchidism as part of the fragile X
      physical phenotype.
  - reference: PMID:8190590
    reference_title: "Do young boys with fragile X syndrome have macroorchidism?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings suggest that macroorchidism occurs in some prepubertal boys with fragile X, but in this series it did not occur until age 6 and usually did not occur until after age 8.
    explanation: >-
      The clinical series demonstrates age-dependent expression; this result does not support a very
      frequent band across all ages.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000053 | Macroorchidism | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies macroorchidism as very frequent in Fragile X syndrome.
  notes: >-
    Orphanet records a very frequent band, applicable especially to adolescent/adult males; the
    cited prepubertal series found macroorchidism in only 1/27 boys aged 2.2-7 years and 7/9 aged
    8-10 years. A single all-age frequency is not assigned.
- name: Elongated Face
  category: Craniofacial
  frequency: FREQUENT
  description: >-
    A long face is part of the characteristic fragile X physical gestalt and can
    become more apparent with age.
  phenotype_term:
    preferred_term: Long face
    term:
      id: HP:0000276
      label: Long face
  evidence:
  - reference: PMID:9678703
    reference_title: "The fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      This directly supports long face as part of the fragile X physical
      phenotype.
  - reference: PMID:8237919
    reference_title: "A study of the physical, behavioral, and medical phenotype, including anthropometric measures, of females with fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females.
    explanation: >-
      This supports long face across affected males and females.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000276 | Long face | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies long face as frequent in Fragile X syndrome.
- name: Large Ears
  category: Craniofacial
  frequency: FREQUENT
  description: >-
    Large ears (macrotia) are a recognized craniofacial feature of fragile X syndrome, distinct from
    outward protrusion of the ears.
  phenotype_term:
    preferred_term: Large ears
    term:
      id: HP:0000400
      label: Macrotia
  evidence:
  - reference: PMID:9678703
    reference_title: "The fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      The review explicitly describes large ears; protrusion is represented separately.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000400 | Macrotia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies macrotia, the HPO term used here, as frequent in Fragile X syndrome.
- name: Chronic Otitis Media
  category: Otolaryngological
  frequency: VERY_FREQUENT
  description: >-
    Chronic otitis media is a very frequent otological comorbidity in Fragile X
    syndrome.
  phenotype_term:
    preferred_term: Chronic otitis media
    term:
      id: HP:0000389
      label: Chronic otitis media
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000389 | Chronic otitis media | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies chronic otitis media as very frequent in Fragile X syndrome.
  sequelae:
  - target: Conductive Hearing Impairment
    causal_link_type: DIRECT
    description: >-
      Middle-ear disease can impair sound conduction.
    evidence:
    - reference: PMID:28420439
      reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: |-
        FXS children tend to have recurrent otitis media,
        which may lead to conductive hearing loss [6, 8, 9, 11].
      explanation: >-
        The review describes hearing loss as a possible complication of recurrent otitis; the
        mechanism also applies to persistent middle-ear disease.
      directness: INDIRECT
- name: Joint Hypermobility
  category: Musculoskeletal
  description: >-
    Hyperextensible joints are part of the connective-tissue physical phenotype
    in fragile X syndrome.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:8237919
    reference_title: "A study of the physical, behavioral, and medical phenotype, including anthropometric measures, of females with fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females.
    explanation: >-
      This directly supports hyperextensible joints as part of the fragile X
      physical phenotype.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001382 | Joint hypermobility | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies joint hypermobility as very frequent in Fragile X syndrome.
  notes: >-
    Orphanet assigns a very frequent band, whereas Ciaccio et al. (PMID:28420439) describe joint
    hypermobility in about half of patients. No single band is assigned across these differing
    sources.
- name: Pes Planus
  category: Musculoskeletal
  description: >-
    Pes planus is a frequent connective-tissue and musculoskeletal feature in
    Orphanet's Fragile X syndrome phenotype profile.
  phenotype_term:
    preferred_term: Pes planus
    term:
      id: HP:0001763
      label: Pes planus
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001763 | Pes planus | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies pes planus as very frequent in Fragile X syndrome.
  notes: >-
    Orphanet assigns a very frequent band, whereas the male clinical-features table in Ciaccio et
    al. (PMID:28420439) reports flat feet in 29-69%. No single band is assigned across these
    differing sources.
- name: Macrocephaly
  category: Craniofacial
  description: >-
    Macrocephaly is reported in fragile X syndrome. Published frequency estimates differ, and head
    circumference above the 50th percentile alone does not establish macrocephaly.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0000256 | Macrocephaly | Frequent (79-30%)
    explanation: >-
      Orphanet explicitly annotates macrocephaly in fragile X syndrome.
  notes: >-
    Ciaccio et al. (PMID:28420439) report 81% in a male clinical-features table but describe head
    circumference above the 50th percentile in the text. That threshold is not diagnostic of
    macrocephaly or relative macrocephaly; the table percentage is not propagated as a disease-wide
    band.
- name: High Palate
  category: Craniofacial
  frequency: VERY_FREQUENT
  description: >-
    A high-arched palate is part of the connective-tissue/skeletal physical
    phenotype of fragile X syndrome.
  phenotype_term:
    preferred_term: High-arched palate
    term:
      id: HP:0000218
      label: High palate
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Skel-
      etal signs may include a high-arched palate, scoliosis, pectus
      excavatum, and flat feet [6, 9, 24, 39, 40].
    explanation: >-
      This review lists a high-arched palate among the skeletal/connective-tissue
      signs of fragile X syndrome.
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "High-arched palate 94%"
    explanation: >-
      The review's clinical-features table reports a high-arched palate in 94%
      of FXS males, supporting a very frequent band.
  notes: >-
    The frequency band comes from the cited review table of clinical features in FXS males; it is
    not an estimate for affected females.
- name: Mandibular Prognathia
  category: Craniofacial
  frequency: VERY_FREQUENT
  description: >-
    A prominent jaw is part of the characteristic long-face craniofacial gestalt
    of fragile X syndrome, becoming more distinctive with age.
  phenotype_term:
    preferred_term: Prominent jaw
    term:
      id: HP:0000303
      label: Mandibular prognathia
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Other reported facial features are the
      prominence of the jaw, a high-arched palate, puffiness
      around the eyes, long palpebral fissures, closely spaced
      eyes, epicanthal folds, strabismus, flat nasal bridge, broad
      nose, broad philtrum, and facial hypotonia (demonstrated
      by slackness of the lower jaw)
    explanation: >-
      This review lists prominence of the jaw among the facial features of
      fragile X syndrome.
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prominent jaw 80%"
    explanation: >-
      The review's clinical-features table reports a prominent jaw in 80% of FXS
      males, supporting a very frequent band.
  notes: >-
    The frequency band comes from the cited review table of clinical features in FXS males; it is
    not an estimate for affected females.
- name: Strabismus
  category: Ophthalmologic
  description: >-
    Strabismus is an ocular feature that occurs more often in fragile X syndrome
    than in the general population.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Strabismus
      and refractive errors have a higher prevalence in FXS than
      in the general population
    explanation: >-
      This review supports strabismus as an ocular manifestation enriched in
      fragile X syndrome relative to the general population.
- name: Pectus Excavatum
  category: Musculoskeletal
  frequency: FREQUENT
  description: >-
    Pectus excavatum is a skeletal/connective-tissue feature in the fragile X
    physical phenotype.
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Skel-
      etal signs may include a high-arched palate, scoliosis, pectus
      excavatum, and flat feet [6, 9, 24, 39, 40].
    explanation: >-
      This review lists pectus excavatum among the skeletal signs of fragile X
      syndrome.
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pectus excavatum 50%"
    explanation: >-
      The review's clinical-features table reports pectus excavatum in 50% of
      FXS males, supporting a frequent band.
  notes: >-
    The frequency band comes from the cited review table of clinical features in FXS males; it is
    not an estimate for affected females.
- name: Mitral Valve Prolapse
  category: Cardiovascular
  description: >-
    Fragile X syndrome shares connective-tissue cardiac features with connective
    tissue disorders; mitral valve prolapse and aortic root dilatation are the
    recurrent cardiac findings.
  phenotype_term:
    preferred_term: Mitral valve prolapse
    term:
      id: HP:0001634
      label: Mitral valve prolapse
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Recurrent findings are aortic
      root dilatation (approximately 25% of the patients) and
      mitral valve prolapse (3 –50%)
    explanation: >-
      This review identifies mitral valve prolapse (with aortic root dilatation)
      as the recurrent connective-tissue cardiac finding in fragile X syndrome.
- name: Aggressive Behavior
  category: Behavioral
  frequency: VERY_FREQUENT
  description: >-
    Aggressive behavior is a prominent behavioral challenge in fragile X
    syndrome across both sexes.
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      This latter as-
      pect has been fully examined recently by Wheeler et al.,
      who demonstrate that 90% of individuals with FXS,
      both males and females, were reported to be engaged
      in at least one aggressive act in the previous 12 months
      [37].
    explanation: >-
      This review reports that 90% of individuals with fragile X syndrome
      engaged in at least one aggressive act in the prior year, supporting a
      very frequent band.
- name: Obesity
  category: Metabolic
  description: >-
    Obesity is reported in fragile X syndrome. Published estimates that combine obesity and
    overweight are not obesity-specific frequencies.
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Metabolic problems are common and well reported,
      with obesity and overweight being quite frequent in both
      sexes [6, 8, 42].
    explanation: >-
      The review supports occurrence of obesity. Its combined obesity/overweight percentages cannot
      be assigned to obesity alone.
- name: Protruding Ears
  category: Craniofacial
  description: >-
    Protruding ears are a characteristic craniofacial finding, distinct from macrotia.
  phenotype_term:
    preferred_term: Protruding ear
    term:
      id: HP:0000411
      label: Protruding ear
  evidence:
  - reference: PMID:9678703
    reference_title: The fragile X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      The review explicitly describes protruding ears as part of the physical phenotype.
- name: Scoliosis
  category: Musculoskeletal
  description: >-
    Scoliosis is a recognized musculoskeletal manifestation of fragile X syndrome.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:20301558
    reference_title: FMR1 Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media.
    explanation: >-
      GeneReviews lists scoliosis among medical manifestations of full-mutation FXS.
- name: Aortic Root Dilatation
  category: Cardiovascular
  description: >-
    Aortic root dilatation is reported particularly in adults with fragile X syndrome.
  phenotype_term:
    preferred_term: Aortic root aneurysm
    term:
      id: HP:0002616
      label: Aortic root aneurysm
  evidence:
  - reference: PMID:20301558
    reference_title: FMR1 Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Adults may have mitral valve prolapse or aortic root dilatation.
    explanation: >-
      This sentence is in the full-mutation FXS clinical-characteristics section, before the separate FXTAS description.
- name: Delayed Gross Motor Development
  category: Neurological
  description: >-
    Delayed walking is part of the early developmental phenotype.
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      The psychomotor delay involves both walking
      age (mean = 2,12 years) and age at first words (mean =
      2,43 years) [11].
    explanation: >-
      The review reports delayed walking and first words; this supports gross motor delay without
      assigning a language-plus-motor denominator to either component.
- name: Recurrent Hand Flapping
  category: Behavioral
  description: >-
    Stereotyped hand flapping is part of the fragile X behavioral phenotype.
  phenotype_term:
    preferred_term: Recurrent hand flapping
    term:
      id: HP:0100023
      label: Recurrent hand flapping
  evidence:
  - reference: PMID:14730483
    reference_title: "[Can the behavioural phenotype of fragile X syndrome be attributed to mental retardation and to attention deficit hyperactivity disorder?]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness.
    explanation: >-
      The human clinical comparison explicitly describes stereotypical hand flapping.
- name: Self-injurious Behavior
  category: Behavioral
  description: >-
    Self-injurious behavior, including hand biting, occurs in fragile X syndrome.
  phenotype_term:
    preferred_term: Self-injurious behavior
    term:
      id: HP:0100716
      label: Self-injurious behavior
  evidence:
  - reference: PMID:24346713
    reference_title: From FMRP function to potential therapies for fragile X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: FXS is characterized by mild to severe intellectual disability, susceptibility to seizures, hyperactivity, hypersensitivity to sensory stimuli, and autistic traits such as social anxiety, attention deficit, hand biting or flapping (repetitive behavior), and poor eye contact.
    explanation: >-
      The human phenotype overview describes hand biting before discussing animal-model recapitulation.
- name: EEG with Centrotemporal Epileptiform Discharges
  category: Neurological
  description: >-
    Centrotemporal spikes are a reported EEG pattern. Epileptiform abnormalities can occur in
    individuals without clinical seizures.
  phenotype_term:
    preferred_term: EEG with centrotemporal epileptiform discharges
    term:
      id: HP:0033721
      label: EEG with centrotemporal epileptiform discharges
  evidence:
  - reference: PMID:12418611
    reference_title: Epilepsy in fragile X syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: EEG findings were available for 35 individuals (13 of 16 with seizures and 22 of 120 without seizures) and showed an epileptiform abnormality in 10 (77%) individuals with seizures and five (23%) individuals without seizures--the most common epileptiform pattern being centrotemporal spikes.
    explanation: >-
      The primary clinical series supports the specific EEG pattern and separates the seizure and
      non-seizure subgroups. The quoted subgroup percentages apply to any epileptiform abnormality,
      not specifically centrotemporal spikes.
  reports_on:
  - target: Neuronal hyperexcitability
    relationship: READOUT_OF
    description: >-
      Epileptiform discharges reflect abnormal neuronal excitability; their occurrence without
      seizures precludes treating them as a consequence of clinical seizures.
- name: Conductive Hearing Impairment
  category: Otolaryngological
  description: >-
    Conductive hearing impairment may complicate recurrent middle-ear disease in children with fragile X syndrome.
  phenotype_term:
    preferred_term: Conductive hearing impairment
    term:
      id: HP:0000405
      label: Conductive hearing impairment
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      FXS children tend to have recurrent otitis media,
      which may lead to conductive hearing loss [6, 8, 9, 11].
    explanation: >-
      The review explicitly describes conductive hearing loss as a complication of otitis media.
biochemical:
- name: FMRP
  presence: Absent or reduced
  context: Absent in full-mutation males; variably reduced in females and mosaic individuals.
  evidence:
  - reference: PMID:27713816
    reference_title: "CGG-repeat dynamics and FMR1 gene silencing in fragile X syndrome stem cells and stem cell-derived neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory.
    explanation: >-
      This supports FMRP loss as the biochemical consequence of full-mutation
      FMR1 silencing.
genetic:
- name: FMR1
  gene_term:
    preferred_term: FMR1
    term:
      id: hgnc:3775
      label: FMR1
  association: Causative full-mutation CGG repeat expansion
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    X-linked repeat expansion disorder. Full-mutation alleles have more than
    200 CGG repeats in the FMR1 5' UTR and usually silence FMR1 expression.
  variants:
  - name: FMR1 full-mutation CGG repeat expansion
    description: >-
      Pathogenic expansion of the FMR1 5' UTR CGG repeat above 200 repeats,
      associated with methylation-mediated loss of FMR1 expression and FMRP.
    gene:
      preferred_term: FMR1
      term:
        id: hgnc:3775
        label: FMR1
    type: trinucleotide repeat expansion
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: FMR1 expression
      regulatory_category: LOE
      regulatory_element_type: PROMOTER
      description: >-
        Repeat expansion and methylation abolish or markedly reduce FMR1
        expression across affected tissues.
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is caused by an alteration of the FMR1 gene, which maps at the Xq27.3 band: more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS.
    explanation: >-
      This review supports FMR1 as the causal gene and identifies full-mutation
      CGG repeat expansion as the dominant pathogenic variant class.
  - reference: PMID:24346713
    reference_title: "From FMRP function to potential therapies for fragile X syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 (FMR1) gene.
    explanation: >-
      This supports the causal FMR1 gene-disease relationship.
  - reference: CGGV:assertion_e491d278-7123-434c-8de3-46e16afb4037-2019-06-03T160000.000Z
    reference_title: "FMR1 / fragile X syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FMR1 | HGNC:3775 | fragile X syndrome | MONDO:0010383 | XL | Definitive"
    explanation: ClinGen classifies the FMR1-fragile X syndrome gene-disease relationship as definitive with X-linked inheritance.
treatments:
- name: Behavioral Therapy
  treatment_term:
    preferred_term: applied behavior analysis therapy
    term:
      id: NCIT:C15184
      label: Behavioral Intervention
  description: Applied behavior analysis and educational interventions for cognitive and behavioral symptoms.
- name: Speech Therapy
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: speech therapy
    term:
      id: NCIT:C159273
      label: Speech Language Therapy
  description: Language and communication support.
- name: Stimulant Medications
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: CNS Stimulant
      term:
        id: NCIT:C47795
        label: CNS Stimulant
  description: For attention deficit and hyperactivity symptoms.
  target_mechanisms:
  - target: Neurodevelopmental circuit dysfunction
    treatment_effect: MODULATES
    description: >-
      CNS stimulants enhance dopaminergic and noradrenergic signaling in
      prefrontal circuits, partially compensating for FMRP-loss-driven
      synaptic dysfunction underlying attention deficit and hyperactivity.
- name: SSRIs
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Selective Serotonin Reuptake Inhibitor
      term:
        id: NCIT:C94725
        label: Selective Serotonin Reuptake Inhibitor
  description: For anxiety and mood symptoms.
  target_mechanisms:
  - target: Neurodevelopmental circuit dysfunction
    treatment_effect: MODULATES
    description: >-
      SSRIs modulate serotonergic signaling in amygdalar and prefrontal
      circuits, addressing anxiety and mood dysregulation that arises
      downstream of FMRP-loss synaptic protein synthesis imbalance.
- name: Genetic Counseling
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: Family screening for FMR1 expansion carriers, prenatal testing options.
- name: Alpha-Adrenergic Agonists
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Alpha-Adrenergic Agonist
      term:
        id: NCIT:C29709
        label: Alpha-Adrenergic Agonist
  description: >-
    Alpha-adrenergic agonists (e.g., clonidine, guanfacine) for hyperactivity
    and hyperarousal.
  target_mechanisms:
  - target: Neurodevelopmental circuit dysfunction
    treatment_effect: MODULATES
    description: >-
      Alpha-adrenergic agonists dampen noradrenergic hyperarousal, addressing
      hyperactivity and overarousal in fragile X syndrome.
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      alpha-agonists for hyperactivity and overarousal
    explanation: >-
      This review lists alpha-agonists as pharmacotherapy for hyperactivity and
      overarousal in fragile X syndrome.
- name: Antipsychotics
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Antipsychotic Agent
      term:
        id: NCIT:C29710
        label: Antipsychotic Agent
  description: >-
    Atypical antipsychotics for irritability and aggressive behavior.
  target_mechanisms:
  - target: Neurodevelopmental circuit dysfunction
    treatment_effect: MODULATES
    description: >-
      Antipsychotics target irritability and aggression, common behavioral
      challenges in fragile X syndrome.
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      In approximately 60% of pa-
      tients, drug treatment for psychological issues helped
      the remission of some symptoms; in particular, stimu-
      lants can be used to improve attention and hyperactivity,
      SSRIs for anxiety, alpha-agonists for hyperactivity and
      overarousal, and antipsychotics for irritable and aggres-
      sive behaviours [91].
    explanation: >-
      This review lists antipsychotics as pharmacotherapy for irritable and
      aggressive behavior in fragile X syndrome.
- name: Minocycline
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: minocycline
      term:
        id: CHEBI:50694
        label: minocycline
  description: >-
    Minocycline, a matrix metalloproteinase-9 inhibitor under investigation for
    fragile X syndrome, with reported benefit especially in young children.
  target_mechanisms:
  - target: Dendritic spine and synapse maturation abnormality
    treatment_effect: MODULATES
    description: >-
      Minocycline inhibits matrix metalloproteinase-9 (elevated with FMRP loss)
      and is reported to strengthen synaptic connections in young children with
      fragile X syndrome.
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is currently under study for FXS treatment and seems to have its greatest effect in young children, where it strengthens synaptic connections and enhances cognitive
    explanation: >-
      This review describes minocycline as under study for fragile X syndrome
      with the greatest reported effect in young children.
clinical_trials:
- name: NCT02920892
  phase: PHASE_III
  status: COMPLETED
  description: >-
    FXLEARN phase 3 randomized trial of AFQ056/mavoglurant for language
    learning in young children with fragile X syndrome; the published trial did
    not show significant benefit over placebo on the primary WCS language
    outcome.
  target_phenotypes:
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: clinicaltrials:NCT02920892
    reference_title: Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The purpose of this clinical trial is to investigate the impact of AFQ056
      on language learning in 3-6 year old children with Fragile X Syndrome
      (FXS).
    explanation: >-
      ClinicalTrials.gov documents the AFQ056 language-learning trial in young
      children with fragile X syndrome.
  - reference: PMID:37651202
    reference_title: "Effects of AFQ056 on language learning in fragile X syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although both groups made language progress and there were no safety
      issues, the change in WCS score during the placebo-controlled period was
      not significantly different between the AFQ056 and placebo-treated
      groups, nor were there any significant between-group differences in
      change in any secondary measures.
    explanation: >-
      The published FXLEARN report supports the completed phase 3 trial and its
      negative primary and secondary efficacy results.
- name: NCT03569631
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase 2a randomized double-blind crossover trial of BPN14770/zatolmilast in
    adult males with fragile X syndrome, with published cognition, language,
    daily-functioning, and EEG biomarker analyses.
  target_phenotypes:
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT03569631
    reference_title: A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a single-center, randomized, double-blind, 2-period crossover
      study to explore the effects of BPN14770 on cognitive function and
      behavior in subjects with Fragile X Syndrome.
    explanation: >-
      ClinicalTrials.gov documents the BPN14770 crossover trial in adult males
      with fragile X syndrome.
  - reference: DOI:10.1186/s13229-024-00626-0
    reference_title: "Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A recent phase 2a clinical trial testing BPN14770, a phosphodiesterase 4D
      inhibitor, showed improved cognition in 30 adult males with FXS on drug
      relative to placebo.
    explanation: >-
      The Molecular Autism biomarker analysis supports the phase 2a BPN14770
      trial and its reported cognition signal.

references:
- reference: PMID:20301558
  title: "FMR1 Disorders."
  tags:
  - GeneReviews
  findings: []
datasets:
- accession: geo:GSE296077
  title: Metabolic Reprogramming during Human Neuron Differentiation Identifies Glutaminase as a Key Determinant in Fragile X Syndrome
  description: Metabolic homeostasis gone awry is a contributor to, if not an underlying cause of, several neurologic disorders. Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by a trinucleotide repeat expansion in FMR1 and consequent loss of the encoded protein FMRP, which results in downstream molecular, neurologic, and mitochondrial deficits that are linked to cognitive impairment. In human postmortem brain, many metabolites and solute carrier proteins are coordinately dysregulated, which also occurs during differentiation of human iPSCs into excitatory neurons.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 10
  publication: PMID:41557506
  notes: Identified by GEO DataSets index search for Fragile X Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE202895
  title: Fragile X Syndrome Patient–Derived Neurons Developing in the Mouse Brain Show FMR1-Dependent Phenotypes
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 8
  publication: PMID:36372569
  notes: Identified by GEO DataSets index search for Fragile X Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE202179
  title: Antisense Oligonucleotide Rescue of CGG Expansion-Dependent FMR1 Mis-Splicing in Fragile X Syndrome Restores FMRP
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MULTI_OMICS
  sample_count: 57
  publication: PMID:37364131
  notes: Identified by GEO DataSets index search for Fragile X Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS50000000647
  title: Transcriptomic profiling of fragile X syndrome unmethylated full mutation carriers
  description: Total RNA sequencing of fibroblasts from two unrelated FMR1 unmethylated full mutation carriers, a fragile X patient and a control individual. The existence of rare, unmethylated full mutation carriers who carry the mutation that causes fragile X syndrome but do not gain methylation at the locus offers a rare opportunity to study the mechanisms underlying fragile X syndrome. This study aims to compare the transcriptomes of these four individuals in order to elucidate the mechanism behind the methylation a the FMR1 CGG repeat expansion that causes Fragile X syndrome.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Fragile X Syndrome"); description-level mentions were not accepted. EGA study_type: RNASeq. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS50000000648
  title: Genomic profiling of fragile X syndrome unmethylated full mutation carriers
  description: Whole genome sequencing of two unrelated FMR1 unmethylated full mutation carriers. The existence of rare, unmethylated full mutation carriers who carry the mutation that causes fragile X syndrome but do not gain methylation at the locus offers a rare opportunity to study the mechanisms underlying fragile X syndrome. This study aims to investigate the genomic variants in these individuals alongside transcriptomic data to elucidate underlying genomic variants behind transcriptomic differences observed in UFM individuals.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WGS
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Fragile X Syndrome"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: massive:MSV000081061
  title: De Novo Proteome in Fragile X Syndrome
  description: Elevated translation has been reported in multiple models of fragile X syndrome (FXS) and in FXS individuals, however, whether it is limited to fragile X mental retardation protein (FMRP) target mRNAs or neuronal activity-derived conditions remains unclear. We examined this question by measuring the de novo proteome of the Fmr1 knockout (KO) mouse hippocampus compared to normal littermates in steady-state and mGluR-stimulated conditions.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Fragile X Syndrome"). Retrieved 2026-08-02.
notes: >-
  FMR1 premutation alleles (55-200 CGG repeats) confer risks for FXTAS and FXPOI, which are distinct
  FMR1-related disorders rather than subtypes of full-mutation fragile X syndrome. Rare non-repeat
  FMR1 loss-of-function variants can also cause fragile X syndrome.
discussions:
- discussion_id: unresolved_connective_tissue_and_craniofacial_mechanisms
  kind: KNOWLEDGE_GAP
  prompt: Which tissue mechanisms connect FMRP deficiency to the connective-tissue and craniofacial manifestations of fragile X syndrome?
  attaches_to:
  - phenotypes#Elongated Face
  - phenotypes#Large Ears
  - phenotypes#Protruding Ears
  - phenotypes#Joint Hypermobility
  - phenotypes#Pes Planus
  - phenotypes#High Palate
  - phenotypes#Mandibular Prognathia
  - phenotypes#Pectus Excavatum
  - phenotypes#Scoliosis
  - phenotypes#Mitral Valve Prolapse
  - phenotypes#Aortic Root Dilatation
  rationale: >-
    The prior physical-phenotype node restated a clinical feature list and assigned fibroblast and
    developmental processes without mechanistic evidence. The clinical literature supports these
    findings, but the cited review explicitly leaves the biochemical and molecular explanation
    unresolved; no shared causal mechanism is asserted here.
  evidence:
  - reference: PMID:28420439
    reference_title: "Fragile X syndrome: a review of clinical and molecular diagnoses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Although a specific ab-
      normality of the connective tissue has not yet been
      shown, the prevalence of connective tissue signs has sug-
      gested that there is an underlying connective tissue
      anomaly, perhaps similar to that observed in CTDs (in
      particular, Marfan Syndrome and Ehlers-Danlos Syn-
      drome); the precise association between FXS and signs
      of connective tissue abnormality still awaits biochemical
      and molecular explanation [38].
    explanation: >-
      The review explicitly identifies the unresolved molecular basis of connective-tissue signs.
- discussion_id: macroorchidism_model_to_human_gap
  kind: HUMAN_MODEL_MISMATCH
  prompt: Does increased developmental Sertoli-cell proliferation explain macroorchidism in human fragile X syndrome as it does in Fmr1 knockout mice?
  attaches_to:
  - phenotypes#Macroorchidism
  rationale: >-
    A mouse experiment establishes increased Sertoli-cell proliferation, but the human clinical
    sources document enlargement and age dependence without establishing that cellular intermediate.
    The mouse mechanism is retained as a research lead rather than a proven human causal edge.
  evidence:
  - reference: PMID:9421410
    reference_title: Macroorchidism in FMR1 knockout mice is caused by increased Sertoli cell proliferation during testicular development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We conclude that macroorchidism in Fmr1 knockout male mice is caused by an increased rate of Sertoli cell proliferation.
    explanation: >-
      Direct model-organism evidence; the corresponding human mechanism remains unverified.
  proposed_experiments:
  - name: Compare human testicular cell composition
    description: Quantify Sertoli-cell abundance and developmental proliferation markers in available FXS and age-matched control testicular specimens to test whether the mouse cellular mechanism translates to humans.
    experiment_id: human_sertoli_cell_composition
- discussion_id: phenotype_specific_neurodevelopmental_and_multisystem_intermediates
  kind: KNOWLEDGE_GAP
  prompt: Which phenotype-specific intermediates explain the remaining neurologic, behavioral, growth, ocular, gastrointestinal and middle-ear findings?
  attaches_to:
  - phenotypes#Sleep Disturbance
  - phenotypes#Gastroesophageal Reflux
  - phenotypes#Attention Deficit Hyperactivity Disorder
  - phenotypes#Delayed Speech and Language Development
  - phenotypes#Abnormal Speech Pattern
  - phenotypes#Hypotonia
  - phenotypes#Chronic Otitis Media
  - phenotypes#Macrocephaly
  - phenotypes#Strabismus
  - phenotypes#Aggressive Behavior
  - phenotypes#Obesity
  - phenotypes#Delayed Gross Motor Development
  - phenotypes#Recurrent Hand Flapping
  - phenotypes#Self-injurious Behavior
  rationale: >-
    FMRP loss and synaptic dysfunction establish the broad neurodevelopmental disease mechanism, but
    the reviewed clinical evidence does not isolate a causal chain for each of these findings. Sleep
    and behavioral features have plausible neural contributors; growth, ocular, gastrointestinal and
    otological findings require separate tissue explanations. These phenotype associations are
    retained without adding arrows solely from coexistence.
- discussion_id: fxs_mglur5_translation_window
  prompt: >-
    Did the mGluR5-antagonist trials fail because the synaptic translation arm
    does not drive the clinical phenotype, or because they treated adolescents
    and adults, after the developmental window, against behavioral rating
    endpoints with a high placebo response?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation
  - mechanistic_hypotheses#canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model
  - clinical_trials#NCT02920892
  rationale: >-
    The mGluR theory's one testable clinical prediction has now failed twice
    over: two phase 2b mavoglurant trials in adolescents and adults missed their
    behavioral primary endpoints, and the later FXLEARN phase 3 trial in 3 to 6
    year olds missed its primary language outcome. Yet mavoglurant did move
    biobehavioral measures in the same patients, so the drug was reaching its
    target. Nothing published so far separates the two explanations, and the
    distinction matters for what this entry asserts: whether the synaptic
    translation node is the therapeutically relevant driver of the cognitive
    and behavioral phenotype, or one arm among several. Expert reviews attribute
    the gap to trial design rather than to the model, but that is opinion rather
    than a result and should not be curated as a finding.
  proposed_experiments:
  - experiment_id: fxs_early_intervention_eeg_endpoint_trial
    name: Early-intervention trial with EEG biomarkers as co-primary endpoints
    description: >-
      Randomized controlled trial of an mGluR5 modulator, with or without a
      GABA-B agonist, in children aged 2 to 6, using auditory inter-trial phase
      coherence and resting gamma power as co-primary endpoints alongside
      adaptive behavioral measures. Both EEG measures are abnormal in Fmr1
      knockout mice from early postnatal ages and have human counterparts, which
      makes them candidate pharmacodynamic markers for a population in whom
      behavioral rating scales perform poorly.
    would_support:
    - pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation
    supporting_outcome:
    - >-
        EEG measures normalize and developmental trajectory improves, indicating
        that treatment timing rather than model validity explains the earlier
        failures.
    refuting_outcome:
    - >-
        EEG measures normalize while behavior does not, indicating that correcting
        the synaptic translation arm is insufficient and that the parallel
        effector arms carry a substantial part of the clinical phenotype.
  evidence:
  - reference: PMID:30451888
    reference_title: "Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate any behavioral benefits in two 12-week, randomized, placebo-controlled, double-blind, phase IIb studies in adults and adolescents with FXS.
    explanation: >-
      Documents the failure of the mGluR theory's central therapeutic
      prediction in the age group tested, and the mismatch with the preclinical
      result that motivated the trials.
  - reference: PMID:30653533
    reference_title: "Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The study shows that negative modulation of mGluR5 activity improves eye gaze behavior and alters sympathetically-driven reactivity to faces in patients with FXS, providing preliminary evidence of this drug's impact on behavior in humans with the disorder.
    explanation: >-
      An eye-tracking biobehavioral probe embedded in the same trials did detect
      a drug effect, which is why the endpoint explanation for the failure
      cannot be dismissed.
- discussion_id: fxs_nonsynaptic_effector_arms
  prompt: >-
    Are the nuclear genome-protection and glutaminase-dependent metabolic
    consequences of FMRP loss independent contributors to the fragile X
    phenotype, or downstream of, or incidental to, the cytoplasmic translational
    defect?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#FMRP loss of translational repression
  - pathophysiology#Excess translation of chromatin regulators
  rationale: >-
    FMRP loss has documented consequences that this entry's pathograph does not
    connect to any phenotype. Patient fibroblasts accumulate twice the
    double-strand breaks of controls, with breaks colocalizing with R-loop
    forming sequences under replication stress; patient iPSC-derived neurons
    show reduced glutaminolysis and impaired anaplerotic supply to the TCA
    cycle. Both are measured in patient-derived cells, so neither is a model
    artifact, but neither has been traced to a neural or clinical outcome, and
    no experiment has separated nuclear from cytoplasmic FMRP function. Until
    that is done, the entry curates these as observations rather than as arms of
    the causal chain, and the astrocytic and chromatin arms are curated as nodes
    only because each has an intervention that reverses a downstream phenotype.
  proposed_experiments:
  - experiment_id: fxs_nuclear_vs_cytoplasmic_fmrp_rescue
    name: Compartment-restricted FMRP rescue
    description: >-
      Express nuclear-localization-tagged FMRP against nuclear-export-tagged
      FMRP in FMRP-null cells and neurons, then measure protein synthesis rate,
      mGluR-dependent long-term depression, double-strand breaks, R-loops,
      chromatin marks, and glutaminolysis in each condition.
    would_support:
    - pathophysiology#FMRP loss of translational repression
    supporting_outcome:
    - >-
        Cytoplasmic FMRP alone corrects the genome-instability and metabolic
        readouts, showing they are downstream of the translational defect and need
        no separate arm in the model.
    refuting_outcome:
    - >-
        Only nuclear FMRP corrects the genome-instability readouts, establishing an
        effector arm that the synaptic translation formulation cannot account for.
  evidence:
  - reference: PMID:32966779
    reference_title: "Replication Stress Induces Global Chromosome Breakage in the Fragile X Genome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We report that the genomes of FXS cells are inherently unstable and accumulate twice as many DSBs as those from an unaffected control.
    explanation: >-
      Establishes the genome-instability observation in patient-derived cells.
      The study does not link it to any neural or clinical phenotype, which is
      the gap.
  - reference: PMID:41557506
    reference_title: "Metabolic reprogramming during human neuron differentiation indicates glutaminase as a key determinant in Fragile X syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Metabolic tracing in FXS neurons demonstrates a dearth of glutamine deamidation to glutamate, which reduces anaplerosis into the TCA cycle, potentially hindering the bioenergetic and biosynthetic functions of mitochondria.
    explanation: >-
      Establishes the metabolic observation in patient iPSC-derived neurons. The
      authors themselves hedge the disease link, and no causal test of it has
      been reported.
- discussion_id: fxs_mglur_ltd_age_and_condition_dependence
  prompt: >-
    Is exaggerated mGluR-dependent long-term depression a general property of
    FMRP loss, or an artifact of a narrow mouse age window and the
    pharmacological and metabolic conditions of the slice recording?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation
  rationale: >-
    Exaggerated mGluR-LTD is the signature electrophysiological phenotype of the
    canonical model, but in the Fmr1 knockout mouse it appears only between P30
    and P60, and only when NMDA receptors are pharmacologically blocked; the
    same study concludes that hyperactive GluN2B-containing NMDA receptors, not
    the mGluR arm alone, underlie the difference. The phenotype has never been
    demonstrated in human brain tissue or human neuronal preparations. So the
    entry's mGluR node rests on a mouse measurement whose scope is narrower than
    the claim usually made from it, and the translational status of the
    phenotype is the open question rather than its existence.
  proposed_experiments:
  - experiment_id: fxs_human_mglur_ltd_organoid_test
    name: mGluR-dependent long-term depression in human FXS neural tissue
    description: >-
      Test for exaggerated mGluR-dependent long-term depression in patient
      iPSC-derived brain organoids and, where available, acute human cortical
      tissue, under both standard and NMDA-receptor-blocked conditions and
      across differentiation stages matched to the mouse age window.
    would_support:
    - pathophysiology#Synaptic protein synthesis and mGluR signaling dysregulation
    supporting_outcome:
    - >-
        Human FXS neural tissue shows exaggerated mGluR-dependent long-term
        depression without requiring NMDA-receptor blockade, confirming the
        phenotype translates.
    refuting_outcome:
    - >-
        No difference in human tissue, or a difference only under the same
        pharmacological conditions required in mouse, confining the phenotype to
        the model system.
  evidence:
  - reference: PMID:27656021
    reference_title: "Dysregulated NMDA-Receptor Signaling Inhibits Long-Term Depression in a Mouse Model of Fragile X Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      As expected, in the presence of APV, we found more LTD in the mouse KO than in WT. This, however, was only observed in the p30-60 age group.
    explanation: >-
      States both limits on the phenotype in one sentence pair: it requires
      NMDA-receptor blockade and it is confined to a single postnatal window.

📚

References & Deep Research

References

1

PMID:20301558

FMR1 Disorders.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸

1. Disease Information

Edison Scientific Literature 50 citations 2026-04-25T22:42:57.048086

1. Disease Information

1.1 Overview

FXS is characterized by a broad phenotype including developmental delay, intellectual disability, behavioral dysregulation (anxiety, hyperactivity/ADHD traits, aggression), autistic features, and a set of physical findings (e.g., macroorchidism in males after puberty). (de2025fromdiscoveryto pages 4-6, de2025fromdiscoveryto pages 3-4)

1.2 Key identifiers and synonyms (available from retrieved sources)

OMIM: 300624 (ciaccio2017fragilexsyndrome pages 1-2)
Gene: FMR1; locus Xq27.3 (ciaccio2017fragilexsyndrome pages 1-2)
Common synonym: Martin–Bell syndrome (ciaccio2017fragilexsyndrome pages 1-2)

ICD-10/ICD-11, MeSH, Orphanet/ORPHAcode: Not extractable from the retrieved documents; these need direct retrieval from ICD and Orphanet/MeSH resources.

1.3 Data provenance

The information summarized here is derived from aggregated disease-level resources (peer-reviewed reviews and clinical trial publications), plus primary studies (e.g., population newborn screening study; interventional trials). (berrykravis2024effectsofafq056 pages 1-2, seng2024longitudinalfollowupof pages 1-2, coffee2009incidenceoffragile media 983b62aa)

1.4 Compact identifiers/threshold summary

Item	Value	Source / publication date	URL	Citation
Disease name	Fragile X syndrome (FXS)	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 1-3)
OMIM identifier	OMIM: 300624	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)
Causal gene	FMR1	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
Cytogenetic locus	Xq27.3	Ciaccio et al., 2017; Volianskis, 2024	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2, volianskis2024alterationsinsynaptic pages 15-19)
Common alternate names / synonyms	Martin-Bell syndrome; historical “fragile X mental retardation” terminology appears in older literature	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)
Molecular mechanism summary	CGG trinucleotide-repeat expansion in the 5′ UTR of FMR1 causes hypermethylation/silencing of FMR1 and loss of FMRP in full-mutation FXS	Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
CGG repeat range: normal	5–44 repeats (Ciaccio 2017); ~5–55 repeats (van der Lei & Kooy 2025); about 5–40 repeats (Genovese 2025)	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
CGG repeat range: gray zone / intermediate	45–54 repeats	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)
CGG repeat range: premutation	~55–200 repeats (Ciaccio 2017); 55–200 repeats (Genovese 2025; van der Lei & Kooy 2025)	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
CGG repeat range: full mutation	>200 repeats	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
Prevalence estimate	~1 in 4,000 males and ~1 in 8,000 females	Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 1-3)
Alternate prevalence estimates reported in literature	~1:5,000–7,000 males and ~1:4,000–6,000 females	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)

Table: This table summarizes the core identifiers, synonyms, prevalence figures, and CGG repeat thresholds for Fragile X syndrome from key review sources. It is useful as a compact normalization reference for disease knowledge-base curation.

2. Etiology

2.1 Disease causal factors

Primary cause: A CGG repeat expansion in the 5′UTR of FMR1. Commonly used thresholds across sources: - Normal: ~5–55 repeats (or 5–44 in some classification) (de2025fromdiscoveryto pages 4-6, ciaccio2017fragilexsyndrome pages 1-2) - Premutation: 55–200 repeats (de2025fromdiscoveryto pages 4-6, genovese2025systematicreviewfragile pages 2-4) - Full mutation (FXS): >200 repeats, associated with hypermethylation/silencing and loss of FMRP (de2025fromdiscoveryto pages 4-6, genovese2025systematicreviewfragile pages 2-4)

Mechanistically, when repeat length exceeds ~200, methylation and chromatin changes (histone deacetylation, heterochromatin formation) contribute to transcriptional silencing and loss of FMRP. (volianskis2024alterationsinsynaptic pages 15-19)

Less common molecular causes: Non-repeat FMR1 alterations such as deletions/duplications and SNVs account for <1% of molecular diagnoses in one review. (ciaccio2017fragilexsyndrome pages 1-2)

2.2 Risk factors

Sex: males are generally more severely affected due to having a single X chromosome. (genovese2025systematicreviewfragile pages 2-4)
Repeat instability/anticipation: expansion from premutation to full mutation occurs predominantly during maternal transmission (anticipation). (genovese2025systematicreviewfragile pages 2-4, volianskis2024alterationsinsynaptic pages 15-19)

2.3 Protective factors

No specific genetic or environmental “protective factors” were identified within the retrieved evidence corpus. However, mosaicism (cells with smaller/unmethylated alleles) is associated with better cognitive outcomes, implying partial protection at the molecular/cellular level. (genovese2025systematicreviewfragile pages 7-9)

2.4 Gene–environment interactions

The retrieved corpus did not provide specific, well-supported gene–environment interaction claims for classic FXS.

3. Phenotypes

3.1 Core neurodevelopmental phenotype

Intellectual disability / cognitive impairment: core feature; one review reports typical IQ <70 with male average ~40–55 and female ~65–70. (de2025fromdiscoveryto pages 3-4)
ASD/autistic features: common; ~30–50% of males and ~20% females have autistic behaviors by direct assessment in one review (de2025fromdiscoveryto pages 3-4); a systematic review reports comorbid ASD in “just over 40%” overall (46% males, 16% females). (genovese2025systematicreviewfragile pages 7-9)
Behavioral features: hyperactivity, anxiety, aggression, attention deficits, sensory hyperarousal; ADHD criteria frequently met. (de2025fromdiscoveryto pages 3-4)

3.2 Neurologic comorbidity

Seizures: estimates include ~15–20% of males and ~5% of females (de2025fromdiscoveryto pages 4-6) and 10–20% of boys and 5–10% of girls (ciaccio2017fragilexsyndrome pages 2-3).
EEG abnormalities: ~74–75% of young children show EEG abnormalities; ~1/3 remit by mid-childhood in one systematic review. (genovese2025systematicreviewfragile pages 7-9)

3.3 Physical phenotype and medical comorbidities (examples with frequency where available)

Macroorchidism: 63–95% (males) (ciaccio2017fragilexsyndrome pages 2-3)
Obesity: 53–61% (ciaccio2017fragilexsyndrome pages 2-3)
Recurrent otitis media: 47–97% (ciaccio2017fragilexsyndrome pages 2-3)
GI complaints: ~31% (ciaccio2017fragilexsyndrome pages 2-3)
Strabismus: 30–55% (young males) (genovese2025systematicreviewfragile pages 6-7)

3.4 Developmental timing and progression

Developmental delay is typically recognized in infancy/early childhood (boys as early as ~6 months; girls ~1 year in a systematic review). (genovese2025systematicreviewfragile pages 7-9)

3.5 Quality-of-life impact

FXS-associated ASD features “emerge in early childhood and impair daily functioning,” and FXS can impair adaptive skills needed for communication, self-care, and social participation, consistent with substantial QOL impact. (de2025fromdiscoveryto pages 3-4)

3.6 Suggested HPO terms (best-effort, not extracted from evidence text)

These are standard phenotype mappings consistent with the reported clinical picture: - Intellectual disability (HP:0001249) - Global developmental delay (HP:0001263) - Autism (HP:0000717) - Seizures (HP:0001250) - Anxiety (HP:0000739) - Attention deficit hyperactivity disorder (HP:0007018) - Macroorchidism (HP:0000049) - Large ears (HP:0000400) - Strabismus (HP:0000486) - Sleep disturbance (HP:0002360)

4. Genetic / Molecular Information

4.1 Causal gene

FMR1 (Xq27.3). (ciaccio2017fragilexsyndrome pages 1-2)

4.2 Pathogenic variant class

Repeat expansion in the 5′UTR CGG tract is the dominant mechanism (>99% of cases in one review), with full mutation generally >200 repeats leading to methylation and silencing. (ciaccio2017fragilexsyndrome pages 1-2, de2025fromdiscoveryto pages 4-6)

4.3 Functional consequence

Loss of function of FMR1 at the expression level (epigenetic silencing) leads to loss of FMRP. (de2025fromdiscoveryto pages 4-6, volianskis2024alterationsinsynaptic pages 15-19)

4.4 Modifier mechanisms

Mosaicism (size or methylation mosaicism) contributes to variable FMRP expression and phenotype variability; mosaicism with partially unmethylated alleles is associated with better cognitive functioning. (genovese2025systematicreviewfragile pages 7-9, volianskis2024alterationsinsynaptic pages 15-19)

4.5 Epigenetic information

FXS full mutation is associated with hypermethylation of FMR1, transcriptional silencing, and heterochromatinization. (volianskis2024alterationsinsynaptic pages 15-19)

5. Environmental Information

FXS is primarily genetic. The retrieved evidence corpus did not provide specific validated environmental exposures that cause classic FXS (as opposed to modifying symptoms). Supportive-care and early intervention (environmental/behavioral supports) affect outcomes but are not etiologic.

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

FMR1 CGG full mutation (>200 repeats) in 5′UTR → 2. hypermethylation and chromatin silencing of FMR1 → 3. loss of FMRP (RNA-binding translational regulator) → 4. dysregulated transport/local translation of synaptic mRNAs and altered protein synthesis → 5. abnormal dendritic spine maturation (immature/elongated spines), altered synaptic plasticity and circuit function → 6. excitatory/inhibitory imbalance and hyperexcitability involving glutamatergic (mGluR5) and GABAergic systems → 7. neurodevelopmental phenotype (ID, ASD traits, behavioral dysregulation, seizures). (de2025fromdiscoveryto pages 4-6, volianskis2024alterationsinsynaptic pages 15-19)

6.2 Implicated pathways (examples)

mGluR5 signaling dysregulation (loss of FMRP’s normal negative regulation) is emphasized as a major mechanistic framework. (de2025fromdiscoveryto pages 4-6)
GABAergic deficits and E/I imbalance are repeatedly described. (de2025fromdiscoveryto pages 4-6)
cAMP signaling abnormalities are noted in human cell lines and models, motivating PDE inhibition strategies. (genovese2025systematicreviewfragile pages 12-13)

6.3 Suggested GO biological process terms (best-effort)

Synaptic signaling (GO:0099536)
Regulation of translation (GO:0006417)
Synaptic plasticity (GO:0048167)
Dendritic spine development (GO:0060998)
Regulation of excitatory postsynaptic potential (GO:0099528)

6.4 Suggested CL cell types (best-effort)

Cortical pyramidal neuron (CL:0000540)
GABAergic interneuron (CL:0000099)

6.5 Suggested UBERON anatomical structures (best-effort)

Cerebral cortex (UBERON:0000956)
Hippocampus (UBERON:0001954)
Prefrontal cortex (UBERON:0001870)

6.6 Molecular profiling / biomarkers (selected)

EEG-based translational biomarkers are emphasized as objective measures; BPN14770 studies specifically analyze auditory N1 ERP and peak alpha frequency (PAF) as treatment-linked physiology measures. (norris2024auditoryn1eventrelated pages 1-2, norris2025rocanalysisof pages 8-10)

7. Anatomical Structures Affected

Organ/system level

Primary involvement is the central nervous system with downstream behavioral, cognitive, and neuropsychiatric manifestations. (de2025fromdiscoveryto pages 4-6, de2025fromdiscoveryto pages 3-4)

Tissue/cell level

FXS pathophysiology is discussed in terms of synaptic dysfunction in neuronal circuits and altered excitatory/inhibitory balance (glutamatergic and GABAergic synapses). (de2025fromdiscoveryto pages 4-6, ntoulas2024multilevelprofilingof pages 1-2)

8. Temporal Development

Onset

Typically early (infancy/early childhood) with developmental delays. (genovese2025systematicreviewfragile pages 7-9)

Progression

FXS is generally described as not markedly worsening over time; however, males may show IQ decline during development/early puberty in some analyses. (genovese2025systematicreviewfragile pages 7-9, genovese2025systematicreviewfragile pages 2-4)

9. Inheritance and Population

9.1 Inheritance

X-linked dominant inheritance pattern is described, with dynamic repeat expansion/anticipation, especially during maternal transmission. (genovese2025systematicreviewfragile pages 2-4, volianskis2024alterationsinsynaptic pages 15-19)

9.2 Epidemiology (selected statistics)

Prevalence: ~1 in 4,000 males and 1 in 8,000 females (genovese2025systematicreviewfragile pages 2-4).
Premutation carrier frequency: ~1 in 250 females and 1 in 800 males (premutation defined 55–200 repeats). (genovese2025systematicreviewfragile pages 2-4)

Newborn-screening derived incidence: In a population screen of 36,124 newborn males, 7 full-mutation FXS cases were confirmed, corresponding to an incidence of 1 in 5161 (95% CI 1/10,653–1/2500). (coffee2009incidenceoffragile media 983b62aa)

10. Diagnostics

10.1 Molecular diagnostic approach (current standard in retrieved sources)

Postnatal testing often includes PCR combined with Southern blot and/or triplet-primed PCR (TP-PCR) to detect FMR1 repeat expansions and assess size. (genovese2025systematicreviewfragile pages 2-4)
Because pathogenicity depends strongly on methylation/silencing, testing commonly includes methylation-sensitive methods. (genovese2025systematicreviewfragile pages 2-4)

10.2 Newborn screening / early detection

A newborn screening approach based on quantitative FMR1 methylation in dried blood spots was developed and used to directly measure incidence in a large male newborn cohort, supporting feasibility of early detection. (coffee2009incidenceoffragile media 983b62aa)

10.3 Prenatal diagnosis

Prenatal diagnostic options described include chorionic villus sampling and amniocentesis when there is family history or known carrier status. (genovese2025systematicreviewfragile pages 2-4)

10.4 Differential diagnosis

Not systematically extractable from the retrieved excerpts.

11. Outcome / Prognosis

FXS is generally not considered directly life-threatening and does not typically show marked neurodegenerative worsening as a primary feature, but it produces lifelong functional challenges requiring support. (genovese2025systematicreviewfragile pages 2-4)

Premutation carriers have distinct late-onset risks (e.g., FXTAS, FXPOI), but these are separate fragile X–associated disorders rather than classic full-mutation FXS. (genovese2025systematicreviewfragile pages 7-9, volianskis2024alterationsinsynaptic pages 15-19)

12. Treatment

12.1 Current clinical practice (real-world implementation)

No FDA-approved disease-modifying medications exist for FXS; management is largely symptom-based and multidisciplinary, including behavioral therapies, speech-language therapy, applied behavior analysis, parent training, and CBT to address communication and behavioral/psychiatric symptoms. (genovese2025systematicreviewfragile pages 10-12)

12.2 Recent clinical trial developments (2023–2024 prioritized)

Key recent peer-reviewed trials and translational biomarker papers: - AFQ056 (mavoglurant) FXLEARN trial (2024, JCI): 99 randomized young children; no benefit over placebo on primary WCS language outcome; strong example of translational gap for mGluR5 NAMs. (berrykravis2024effectsofafq056 pages 1-2, berrykravis2024effectsofafq056 pages 3-5) - Metformin longitudinal follow-up (2024, Frontiers in Psychology): open-label follow-up in n=26 (6–25 years) over 1–3 years; nonverbal IQ and adaptive function stable with no significant decline. (seng2024longitudinalfollowupof pages 3-4) - BPN14770 (zatolmilast) biomarker analysis (2024, Molecular Autism): N1 ERP amplitude correlated with serum drug concentration (rho=0.608, p=0.036 in period-1 drug recipients), supporting an exposure–physiology link; clinical improvements in cognition/language/daily functioning were reported in the trial background. (norris2024auditoryn1eventrelated pages 2-4, norris2024auditoryn1eventrelated pages 1-2)

12.3 Targeted/symptomatic agents with mixed evidence

Reviews summarize mixed/negative outcomes for multiple targeted approaches, with occasional subgroup signals: - Arbaclofen (GABA-B agonist): Phase 3 trials negative overall; some pediatric irritability benefits at higher doses. (protic2025targeteddrugdevelopment pages 4-5) - Ganaxolone (GABAA PAM): safe but primary endpoint negative overall; possible subgroup benefits. (protic2025targeteddrugdevelopment pages 4-5) - Gaboxadol (OV101): early signal with ~60% CGI-I responders in a small study summarized in reviews. (protic2025targeteddrugdevelopment pages 4-5) - Cannabidiol / ZYN002: phase 3 negative overall with post hoc methylation-defined subgroup benefit reported in a review summary. (protic2025razvojciljanefarmakoterapije pages 5-6)

A compact cross-intervention summary is provided below: | Intervention | Mechanism / target | Key study / design | Sample size / population | Primary endpoint(s) / main measures | Main findings reported | NCT ID(s) | Publication date | URL | Citation | |---|---|---|---|---|---|---|---|---|---| | AFQ056 (mavoglurant) | mGluR5 negative allosteric modulator | FXLEARN: large multisite randomized, double-blind, placebo-controlled trial with 4-month placebo lead-in, 2-month dose optimization, 6-month treatment; all participants also received parent-implemented language intervention | 110 enrolled; 99 randomized (50 AFQ056, 49 placebo); 91 completed placebo-controlled period; children age ~3–6 years with FXS | Primary: Weighted Communication Scale (WCS); secondary: objective and parent-reported cognitive/language measures including MSEL, PLS-5, Vineland-3 | No significant difference vs placebo on WCS or secondary measures; both groups improved in language over time; lower-baseline communication subgroup did worse on AFQ056 than placebo in subgroup analysis; no major safety signal | NCT02920892 | 2024-08 | https://doi.org/10.1172/jci171723 | (berrykravis2024effectsofafq056 pages 1-2, berrykravis2024effectsofafq056 pages 3-5, berrykravis2024effectsofafq056 pages 6-7, berrykravis2024effectsofafq056 pages 9-10) | | Metformin | AMPK activation; proposed reduction of MMP-9 / modulation of dysregulated signaling | Open-label longitudinal follow-up after prior controlled exposure; repeated cognitive and adaptive behavior testing over 1–3 years | 26 individuals with FXS (22 males, 4 females), ages 6–25 years | Leiter-III nonverbal IQ; Vineland-3 adaptive behavior | Overall nonverbal IQ and adaptive behavior remained stable; no significant decline over follow-up; small sample and no control group limit inference | NCT05120505 ongoing pediatric RCT also identified in registry; separate follow-up paper is open-label longitudinal | 2024-06 | https://doi.org/10.3389/fpsyg.2024.1305597 | (seng2024longitudinalfollowupof pages 1-2, seng2024longitudinalfollowupof pages 3-4, seng2024longitudinalfollowupof pages 2-3, NCT05120505 chunk 1) | | BPN14770 (zatolmilast) | PDE4D inhibitor; increases cAMP signaling | Phase 2a placebo-controlled crossover trial with EEG biomarker analyses; later exploratory ROC/EEG work | 30 adult males with FXS; EEG subsets smaller due to artifact/data loss | Clinical cognition/language/daily function measures; auditory N1 ERP amplitude; exploratory peak alpha frequency (PAF) | Clinical improvements in cognition, language, and daily functioning were reported; N1 amplitude showed correlation with serum drug concentration, stronger in period-1 drug recipients (rho = 0.608, p = 0.036, N = 12); exploratory PAF increased vs baseline and may be a scalable biomarker | NCT03569631 | 2024-11 (biomarker paper); 2025-05 (exploratory preprint) | https://doi.org/10.1186/s13229-024-00626-0 ; https://doi.org/10.1101/2025.05.29.25328581 | (norris2024auditoryn1eventrelated pages 1-2, norris2024auditoryn1eventrelated pages 2-4, norris2025rocanalysisof pages 1-4, norris2025rocanalysisof pages 8-10) | | Arbaclofen (STX209) | GABA-B agonist | Two Phase 3 placebo-controlled trials in children and in adolescents/adults | Pediatric and adult/adolescent cohorts; registry lists 172 children in NCT01325220 and 125 adolescents/adults in NCT01282268 | Primary behavioral/social withdrawal outcomes; irritability subscales and parent-rated outcomes reported in reviews | Overall primary endpoints not met; pediatric highest-dose group showed improvements on ABC-CFX Irritability and Parenting Stress Index / parent-rated forms; generally well tolerated | NCT01325220; NCT01282268 | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01325220 ; https://clinicaltrials.gov/study/NCT01282268 | (protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 9-10) | | Ganaxolone | GABAA positive allosteric modulator / neurosteroid | Phase 2 randomized crossover trial in children/adolescents | n = 59 in registry/review | Primary: CGI-I | Safe but did not differ from placebo on primary CGI-I endpoint overall; post hoc subgroup benefits reported in participants with higher anxiety or lower cognition | NCT01725152 | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01725152 | (protic2025targeteddrugdevelopment pages 4-5) | | Gaboxadol (OV101) | GABAA agonist / extrasynaptic GABAergic modulation | Phase 2a ROCKET study; additional recruiting single-dose adult study noted in review | ~23 participants in phase 2a response analysis | CGI-I and clinician/caregiver-rated behavioral measures | Well tolerated; about 60% classified as CGI-I responders in phase 2a; initial efficacy signal on hyperactivity, irritability, stereotypy, and anxiety in reported review summaries | NCT06334419 recruiting study noted; ROCKET NCT not provided in evidence excerpt | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://doi.org/10.3390/biomedicines13040805 | (protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 8-9) | | Cannabidiol / ZYN002 | Endocannabinoid system modulation; transdermal CBD formulation | Phase 1/2 open-label and Phase 3 CONNECT-FX reviewed; post hoc methylation-stratified analyses | Sample size not stated in provided evidence excerpt | ADAMS and phase 3 primary endpoint not specified in excerpt | Open-label study showed safety and ADAMS reduction; CONNECT-FX failed primary endpoint overall, but subgroup with ≥90% FMR1 promoter methylation showed benefit, motivating RECONNECT | NCT04977986 recruiting study noted in review | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://doi.org/10.3390/biomedicines13040805 | (protic2025razvojciljanefarmakoterapije pages 5-6, de2025fromdiscoveryto pages 8-9) | | Older mGluR5 program overview (mavoglurant / basimglurant) | mGluR5 negative allosteric modulation | Earlier adult/adolescent Phase 2/2b and extension trials summarized in reviews | Small crossover adult mavoglurant study in 30 adult males; larger adolescent/adult trials listed in reviews/registry | Behavioral endpoints; FXLEARN later used WCS for language learning in young children | Initial small subgroup signal in fully methylated cases did not replicate; larger Phase 2b trials and basimglurant Phase II studies were negative, contributing to skepticism about direct mGluR5 translation from animal models | NCT01357239; NCT01348087; NCT01433354; NCT02920892 | 2024-08 and 2025 review summaries | https://doi.org/10.1172/jci171723 ; https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01357239 | (berrykravis2024effectsofafq056 pages 1-2, protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 9-10) |

Table: This table summarizes key Fragile X syndrome therapeutic studies and trial programs emphasized in the gathered evidence, including recent 2024 findings and older targeted treatment programs. It is useful for comparing mechanisms, study designs, endpoints, outcomes, and trial identifiers across leading pharmacologic approaches.

12.4 Suggested MAXO terms (best-effort)

Pharmacotherapy (MAXO:0000058)
Behavioral therapy (MAXO:0000506)
Speech therapy (MAXO:0001193)
Genetic counseling (MAXO:0000070)

13. Prevention

Primary prevention

Because FXS is inherited, prevention focuses on genetic counseling and reproductive planning for carriers. (genovese2025systematicreviewfragile pages 2-4)

Secondary prevention (screening/early detection)

Newborn screening by methylation assay in dried blood spots has been demonstrated and used to estimate incidence, supporting a potential early-intervention pathway. (coffee2009incidenceoffragile media 983b62aa)

Tertiary prevention

Multidisciplinary management and early developmental/behavioral interventions aim to reduce disability and improve long-term functioning. (genovese2025systematicreviewfragile pages 12-13, genovese2025systematicreviewfragile pages 10-12)

14. Other Species / Natural Disease

The retrieved evidence focuses on model organisms rather than naturally occurring veterinary disease. No naturally occurring non-human clinical syndrome analogous to human FXS was identified in the provided corpus.

15. Model Organisms

A diverse model ecosystem is used to study FMRP function and therapeutics: - Mouse (Fmr1 KO): dominant in vivo model; captures many phenotypes (immature spines, altered LTP/LTD, hyperactivity/anxiety/social changes); key limitations include species differences and differences in timing of FMRP expression vs humans (humans express FMR1 until at least week 10 gestation). (de2025fromdiscoveryto pages 6-8) - Rat (Fmr1 KO): proposed to offer added translational validity; a 2024 study combined behavior, hippocampal electrophysiology, and RNA-seq and found hyperactivity/cognitive deficits plus glutamatergic/GABAergic alterations in PFC and hippocampus. (ntoulas2024multilevelprofilingof pages 1-2) - Drosophila / zebrafish: useful for conserved genetics/pathway discovery; limitations include species differences. (sandoval2024fromwingsto pages 2-3) - Human iPSC neurons and 3D organoids/assembloids: enable study of patient-derived epigenetic FMR1 silencing and human-specific neurodevelopment; limitations include immaturity, reproducibility issues, and inability to model behavior. (sandoval2024fromwingsto pages 5-7)

Expert opinions / analysis (from authoritative sources in retrieved corpus)

A consistent expert view in recent reviews is that translation from strong preclinical signals to clinical efficacy has been limited by patient heterogeneity, inconsistent outcomes, and the need for objective biomarkers and better trial design—highlighted in the context of mGluR5 NAM programs and the field’s shift toward biomarkers (EEG), stratification (methylation status), and gene/reactivation strategies (ASOs, CRISPR-based approaches). (de2025fromdiscoveryto pages 18-19, de2025fromdiscoveryto pages 13-15, berrykravis2024effectsofafq056 pages 1-2)

Key recent statistics (selected)

Prevalence: ~1/4,000 males and ~1/8,000 females. (genovese2025systematicreviewfragile pages 2-4)
Premutation frequency: ~1/250 females; ~1/800 males. (genovese2025systematicreviewfragile pages 2-4)
Newborn-screening incidence in males: 1/5,161 (7/36,124). (coffee2009incidenceoffragile media 983b62aa)
Comorbid ASD in FXS: ~46% males and 16% females (“just over 40% overall”). (genovese2025systematicreviewfragile pages 7-9)
Seizure prevalence: ~15–20% males and ~5% females (review estimate). (de2025fromdiscoveryto pages 4-6)

Limitations of this report (evidence availability)

Specific ontology identifiers (MONDO ID, Orphanet ORPHAcode, MeSH, ICD-10/ICD-11) were not present in the retrieved documents and thus could not be extracted with full citation support.
Some requested sections (environmental risk/protective factors, formal diagnostic criteria, differential diagnosis, survival statistics) were not explicitly quantified in the retrieved excerpts.
Suggested ontology term mappings (HPO/GO/CL/UBERON/MAXO) are provided as best-effort standard mappings rather than extracted identifiers from the cited texts.

References

(de2025fromdiscoveryto pages 4-6): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(genovese2025systematicreviewfragile pages 2-4): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(de2025fromdiscoveryto pages 1-3): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(coffee2009incidenceoffragile media 983b62aa): Bradford Coffee, Krayton Keith, Igor Albizua, Tamika Malone, Julie Mowrey, Stephanie L. Sherman, and Stephen T. Warren. Incidence of fragile x syndrome by newborn screening for methylated fmr1 dna. American journal of human genetics, 85 4:503-14, Oct 2009. URL: https://doi.org/10.1016/j.ajhg.2009.09.007, doi:10.1016/j.ajhg.2009.09.007. This article has 558 citations and is from a highest quality peer-reviewed journal.
(de2025fromdiscoveryto pages 3-4): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(ciaccio2017fragilexsyndrome pages 1-2): Claudia Ciaccio, Laura Fontana, Donatella Milani, Silvia Tabano, Monica Miozzo, and Susanna Esposito. Fragile x syndrome: a review of clinical and molecular diagnoses. Italian Journal of Pediatrics, Apr 2017. URL: https://doi.org/10.1186/s13052-017-0355-y, doi:10.1186/s13052-017-0355-y. This article has 223 citations and is from a peer-reviewed journal.
(berrykravis2024effectsofafq056 pages 1-2): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(seng2024longitudinalfollowupof pages 1-2): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.
(volianskis2024alterationsinsynaptic pages 15-19): RE Volianskis. Alterations in synaptic plasticity in a mouse model of fragile x syndrome. Unknown journal, 2024.
(genovese2025systematicreviewfragile pages 7-9): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(ciaccio2017fragilexsyndrome pages 2-3): Claudia Ciaccio, Laura Fontana, Donatella Milani, Silvia Tabano, Monica Miozzo, and Susanna Esposito. Fragile x syndrome: a review of clinical and molecular diagnoses. Italian Journal of Pediatrics, Apr 2017. URL: https://doi.org/10.1186/s13052-017-0355-y, doi:10.1186/s13052-017-0355-y. This article has 223 citations and is from a peer-reviewed journal.
(genovese2025systematicreviewfragile pages 6-7): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(genovese2025systematicreviewfragile pages 12-13): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(norris2024auditoryn1eventrelated pages 1-2): Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, and Lauren E. Ethridge. Auditory n1 event-related potential amplitude is predictive of serum concentration of bpn14770 in fragile x syndrome. Molecular Autism, Nov 2024. URL: https://doi.org/10.1186/s13229-024-00626-0, doi:10.1186/s13229-024-00626-0. This article has 5 citations and is from a peer-reviewed journal.
(norris2025rocanalysisof pages 8-10): J. E. Norris, E. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Emma K. Auger Ph.D., Abigail H. Outterson Ph.D., Jeremiah Furman, Mark E. Gurney, and Ph.D Lauren E. Ethridge. Roc analysis of biomarker combinations in fragile x syndrome-specific clinical trials: evaluating treatment efficacy via exploratory biomarkers. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.29.25328581, doi:10.1101/2025.05.29.25328581. This article has 1 citations.
(ntoulas2024multilevelprofilingof pages 1-2): George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, Michail-Zois Asprogerakas, Foteini Delis, Leonidas J. Leontiadis, George Trompoukis, Costas Papatheodoropoulos, Dimitrios Gkikas, Dimitrios Valakos, Giannis Vatsellas, Panagiotis K. Politis, Alexia Polissidis, and Katerina Antoniou. Multi-level profiling of the fmr1 ko rat unveils altered behavioral traits along with aberrant glutamatergic function. Translational Psychiatry, Feb 2024. URL: https://doi.org/10.1038/s41398-024-02815-0, doi:10.1038/s41398-024-02815-0. This article has 10 citations and is from a peer-reviewed journal.
(genovese2025systematicreviewfragile pages 10-12): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(berrykravis2024effectsofafq056 pages 3-5): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(seng2024longitudinalfollowupof pages 3-4): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.
(norris2024auditoryn1eventrelated pages 2-4): Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, and Lauren E. Ethridge. Auditory n1 event-related potential amplitude is predictive of serum concentration of bpn14770 in fragile x syndrome. Molecular Autism, Nov 2024. URL: https://doi.org/10.1186/s13229-024-00626-0, doi:10.1186/s13229-024-00626-0. This article has 5 citations and is from a peer-reviewed journal.
(protic2025targeteddrugdevelopment pages 4-5): Dragana Protić, Maja Stojković, and Dejan Budimirović. Targeted drug development in fragile x syndrome: molecular medicine as a key tool in clinical pharmacology. Medicinska istrazivanja, pages 19-19, Jan 2025. URL: https://doi.org/10.5937/medi0-60213, doi:10.5937/medi0-60213. This article has 0 citations.
(protic2025razvojciljanefarmakoterapije pages 5-6): D Protic, M Stojkovic, and D Budimirovic. Razvoj ciljane farmakoterapije za fragilni x sindrom: molekularna medicina kao ključno sredstvo u kliničkoj …. Unknown journal, 2025.
(berrykravis2024effectsofafq056 pages 6-7): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(berrykravis2024effectsofafq056 pages 9-10): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(seng2024longitudinalfollowupof pages 2-3): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.
(NCT05120505 chunk 1): Metformin in Children With Fragile X Syndrome. Children's Hospital of Fudan University. 2021. ClinicalTrials.gov Identifier: NCT05120505
(norris2025rocanalysisof pages 1-4): J. E. Norris, E. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Emma K. Auger Ph.D., Abigail H. Outterson Ph.D., Jeremiah Furman, Mark E. Gurney, and Ph.D Lauren E. Ethridge. Roc analysis of biomarker combinations in fragile x syndrome-specific clinical trials: evaluating treatment efficacy via exploratory biomarkers. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.29.25328581, doi:10.1101/2025.05.29.25328581. This article has 1 citations.
(de2025fromdiscoveryto pages 9-10): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(de2025fromdiscoveryto pages 8-9): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(de2025fromdiscoveryto pages 6-8): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(sandoval2024fromwingsto pages 2-3): Soraya O. Sandoval, Natasha M. Méndez-Albelo, Zhiyan Xu, and Xinyu Zhao. From wings to whiskers to stem cells: why every model matters in fragile x syndrome research. Journal of Neurodevelopmental Disorders, Jun 2024. URL: https://doi.org/10.1186/s11689-024-09545-w, doi:10.1186/s11689-024-09545-w. This article has 3 citations and is from a peer-reviewed journal.
(sandoval2024fromwingsto pages 5-7): Soraya O. Sandoval, Natasha M. Méndez-Albelo, Zhiyan Xu, and Xinyu Zhao. From wings to whiskers to stem cells: why every model matters in fragile x syndrome research. Journal of Neurodevelopmental Disorders, Jun 2024. URL: https://doi.org/10.1186/s11689-024-09545-w, doi:10.1186/s11689-024-09545-w. This article has 3 citations and is from a peer-reviewed journal.
(de2025fromdiscoveryto pages 18-19): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(de2025fromdiscoveryto pages 13-15): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Biochemical Markers

Progression

Prevalence

Related Datasets

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Overview

1.2 Key identifiers and synonyms (available from retrieved sources)

1.3 Data provenance

1.4 Compact identifiers/threshold summary

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core neurodevelopmental phenotype

3.2 Neurologic comorbidity

3.3 Physical phenotype and medical comorbidities (examples with frequency where available)

3.4 Developmental timing and progression

3.5 Quality-of-life impact

3.6 Suggested HPO terms (best-effort, not extracted from evidence text)

4. Genetic / Molecular Information

4.1 Causal gene

4.2 Pathogenic variant class

4.3 Functional consequence

4.4 Modifier mechanisms

4.5 Epigenetic information

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

6.2 Implicated pathways (examples)

6.3 Suggested GO biological process terms (best-effort)

6.4 Suggested CL cell types (best-effort)

6.5 Suggested UBERON anatomical structures (best-effort)

6.6 Molecular profiling / biomarkers (selected)

7. Anatomical Structures Affected

Organ/system level

Tissue/cell level

8. Temporal Development

Onset

Progression

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology (selected statistics)

10. Diagnostics

10.1 Molecular diagnostic approach (current standard in retrieved sources)

10.2 Newborn screening / early detection

10.3 Prenatal diagnosis

10.4 Differential diagnosis

11. Outcome / Prognosis

12. Treatment

12.1 Current clinical practice (real-world implementation)

12.2 Recent clinical trial developments (2023–2024 prioritized)

12.3 Targeted/symptomatic agents with mixed evidence

12.4 Suggested MAXO terms (best-effort)

13. Prevention

Primary prevention

Secondary prevention (screening/early detection)

Tertiary prevention

14. Other Species / Natural Disease

15. Model Organisms

Expert opinions / analysis (from authoritative sources in retrieved corpus)